

# Jurnal Biomedika dan Kesehatan

Jurnal Biomedika dan Kesehatan (J Biomedika dan Kesehat) (pISSN: 2621-539X | eISSN: 2621-5470) is a peer-reviewed journal publish by Faculty of Medicine Universitas Trisakti. Starting in 2024, JBK is a fourth-monthly (March, July, November) medical journal that publishes new research findings on a wide variety of topics of importance to biomedical science and clinical practice (Biochemistry, Epidemiology, Health Profession, Occupational Therapy, medicine, Public Health).

Since 2019, JBK has been indexed and accredited in the Science and Technology Index (SINTA) 3, by the Ministry of Research, Technology and Higher Education Indonesia.

Each manuscript will go through a review process.

SEND ARTICLE





# Current Issue

**Vol. 8 No. 2 (2025)**



**Published:** 2025-07-30

Editorial

## **Understanding The Differences Between Apheresis, Plasmapheresis, and Plasma Exchange: The Urgency of Understanding Terminology in Daily Clinical Practice**

Yasmine Mashabi, Agnes Tineke Waney Rorong, Fauzan Abdillah, Henie Widowati  
111-115



Original Article

fatma Sri kamaonnan LUDIS, Syatran Arrazy, EISKA EISKA, ABDUL KARIM  
Batubara  
116-126

 PDF

### **A Quantitative Survey on Antibiotic Prescribing Pattern in Three Indonesian Hospitals Using Digital Antimicrobial Stewardship**

Ronald Irwanto Natadidjaja, Widyawati Lekok, Aziza Ariyani, Hadianti Adlani, Raymond Adianto, Ronaningtyas Maharani, Hadi Sumarsono, Yenny Yenny, Jihan Samira, Nany Hairunisa, Husnun Amalia, Meutia Atika Faradila, Tubagus Ferdi Fadilah, Joice Viladelvia Kalumpiu, Yuliana Yuliana, Sri Mulyani, Desi Anggiat, Triyoko Septio Marja, Iin Indra Pertiwi, Dianawati Dianawati, Grace Nerry Legoh, Alvin Lekonardo Rantung  
127-141

 PDF

### **Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and Hs-CRP Levels in Type 2 Diabetes Mellitus**

Mustika Anggiane Putri, Patwa Amani, Donna Adriani, Yudhisman Imran  
142-150

 PDF

### **Comparison of Antibody Responses Following COVID-19 Vaccination Between Individuals With and Without Comorbidities**

Isa Bella, Khariri Khariri, Monica Dwi Hartanti, Sisca Sisca, Jihan Samira Thabit, Ida Effendi, Arleen Devita, Thomas Robertus  
151-158

 PDF

### **Relationship between Work Position and Musculoskeletal Disorder (MSDs) Complaints in Palm Harvesters at PTPN IV Tanah Itam Ulu**

Zahra Ananda, Delfriana Ayu Astuty, Fatma Indriani  
159-169

## **Evaluation of The School Health Unit (UKS) Program Based on The CIPP Model in The Implementation of Health Services in Public Elementary School, Tebing Tinggi City**

Fadila Syahrani Purba, Eliska Eliska, Yulia Khairina Ashar  
170-180

 PDF

## **Effectiveness of PKPR Program on Adolescent Reproductive Health at Sigambal Health Center**

Arini Aisyahfira Wijaya, Dewi Agustina, Tri Niswati Utami  
181-191

 PDF

---

### Case Report

## **Epidemiological Case Report of a 2023 cVDPV2 Infection in West Java, Indonesia: Surveillance and Outbreak Response**

Sidik Utoro, Dedi Rachmadi, Lenny Oktorina, Yudi Feriandi  
192-201

 PDF

## **Dilemma of Labor Management in Lethal Anencephalic Fetus**

Imelda Yunitra, Hervi Wiranti, Rully Ayu Nirmalasari, Atut Cich Mayasari,  
RM Denny Dhanardono, Laksmi Maharani  
202-207

 PDF

---

### Review Article



### **Biomarkers of Breast Cancer**

Endah Indriastuti, Fatimah Nur Fitriani, Anwar Djunaidi  
218-231



### **Anti-Inflammatory Effect of Avicennia Plants: Systematic Review**

Fathia Kesuma Dinanti, Benny Diah Madusari, Ary Setya Hernanda  
232-244



[View All Issues >](#)



Jurnal Biomedika dan Kesehatan (JBK) is licensed under a  
Creative Commons Attribution-NonCommercial 4.0 International License.

210962 [View My Stats](#)

© Platform & Workflow by: Open Journal Systems  
Designed by Material Theme

# Editorial Team

[Home](#) / [Editorial Team](#)

## Editorial Team

### Editor in Chief

---

**Husnun Amalia**

Fakultas Kedokteran Universitas Trisakti, Indonesia

Academic profile:     

### Deputy Editor-in-Chief

---

**ML Edy Parwanto**

Fakultas Kedokteran Universitas Trisakti, Indonesia

Academic profile:     

### **Nany Hairunisa**

Fakultas Kedokteran Universitas Trisakti, Indonesia

Academic profile:     

### **Magdalena Wartono**

Fakultas Kedokteran Universitas Trisakti, Indonesia

Academic profile:

---

## **Editorial Boards**

### **Laksmi Maharani**

Fakultas Kedokteran Universitas Trisakti, Indonesia

Academic profile:     

### **Monica Dwi Hartanti**

Fakultas Kedokteran Universitas Trisakti, Indonesia

Academic profile:     

### **Raditya Wratsangka**

Fakultas Kedokteran Universitas Trisakti, Indonesia

Academic profile:     

### **Siti Sugih Hartiningsih**

STIKes Dharma Husada Bandung, Indonesia

Academic profile:     

### **Dito Anugroho**

Universitas Muhammadiyah (Unismuh) Makassar, Indonesia

Academic profile:     

### **Emad Yousif**

Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq

Academic profile:  

### **Norsuhana Omar**

Department of Physiology & Unit of Integrative Medicine,

School of Medical Sciences, Universiti Sains Malaysia (USM),



Academic profile:

### Editorial Office



Jurnal Biomedika dan Kesehatan (JBK) is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

210962 [View My Stats](#)

© Platform & Workflow by: [Open Journal Systems](#)

Designed by [Material Theme](#)

Participants [Edit](#)

mustika anggiane putri (mustika)

Messages	
Note	From
<p>Dear Editor,</p> <p>We are pleased to submit our research manuscript titled "Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and hs-CRP Levels in Type 2 Diabetes Mellitus" for consideration in your esteemed journal.</p> <p>This study addresses a crucial health concern in Indonesia, where diabetes rates are rising rapidly. Our research examines how blood sugar control relates to inflammation markers in diabetic patients, which could help predict heart disease risk. Using data from 59 patients in East Jakarta, we found a significant connection between long-term blood sugar levels (HbA1c) and inflammation markers (hs-CRP). These findings could help doctors better identify diabetic patients at higher risk for heart problems, enabling earlier intervention and potentially saving lives in our community.</p> <p>Thank you for your consideration.</p> <p>Sincerely, Mustika Anggiane Putri</p>	<p>mustika 2025-07-14 12:44 AM</p>

[Add Message](#)

## [JBK] Editor Decision

2025-07-14 11:58 AM

mustika anggiane putri, Amani P, Adriani D, Imran Y:

We have reached a decision regarding your submission to Jurnal Biomedika dan Kesehatan, "Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and hs-CRP Levels in Type 2 Diabetes Mellitus".

Our decision is: Revisions Required

There are suggestions for improving the manuscript from the reviewer, according to the files we have attached.

Article Processing Charge :

Please to pay an Article Processing Charge (APC) in order for your article to be published in our journal with amount of Rp. 2.750.000 rupiah.

The following is a link to make a payment :

<https://forms.gle/9iUSzNs25Dt4zMmG9>

Best regards,  
Husnun Amalia

---

[Jurnal Biomedika dan Kesehatan](#)

Jl. Kyai Tapa No. 260 Kampus B, Grogol, DKI Jakarta 11440

Telp. (021) 5672731 | E-mail: [jbiomedkes@trisakti.ac.id](mailto:jbiomedkes@trisakti.ac.id)

## [JBK] Editor Decision

2025-07-14 11:58 AM

mustika anggiane putri, Amani P, Adriani D, Imran Y:

We have reached a decision regarding your submission to Jurnal Biomedika dan Kesehatan, "Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and hs-CRP Levels in Type 2 Diabetes Mellitus".

Our decision is: Revisions Required

There are suggestions for improving the manuscript from the reviewer, according to the files we have attached.

Article Processing Charge :

Please to pay an Article Processing Charge (APC) in order for your article to be published in our journal with amount of Rp. 2.750.000 rupiah.

The following is a link to make a payment :

<https://forms.gle/9iUSzNs25Dt4zMmG9>

Best regards,  
Husnun Amalia

---

[Jurnal Biomedika dan Kesehatan](#)

Jl. Kyai Tapa No. 260 Kampus B, Grogol, DKI Jakarta 11440

Telp. (021) 5672731 | E-mail: [jbiomedkes@trisakti.ac.id](mailto:jbiomedkes@trisakti.ac.id)

99+

Compose

Mail

**Inbox** 2,386

Chat

Starred

Snoozed

Meet

Sent

**Drafts** 38

More

Labels

Revisi Artikel Inbox ×



**Jurnal Biomedika dan Kesehatan** <jbiomedkes@trisakti.ac.id>  
to me



[Translate to English](#)



Dear Author

Berikut kami kirimkan file hasil review oleh reviewer dan editor. Mohon untuk segera di revisi dan akhir July 2025. Selain itu dimohon untuk melakukan pembayaran APC sebesar Rp.2.750.000 se

Terima Kasih

Salam  
Eka Nurmayanti

--

**Jurnal Biomedika dan Kesehatan**  
Faculty of Medicine, Trisakti University  
Jalan Kyai Tapa No. 260 (Kampus B), Grogol 11440  
Gedung Ki Hadjar Dewantara Lantai 1  
Tlp. 021-565 5578 Ext. 2502



**UNIVERSITAS TRISAKTI**  
*"Is a one stop learning for sustainable development"*  
Kampus A, Jl. Kyai Tapa No.1, Grogol  
Jakarta Barat 11440 - INDONESIA  
[www.trisakti.ac.id](http://www.trisakti.ac.id)  
(t) +62-21.566 3232, (f) +62-21.567 3001

**2 Attachments** • Scanned by Gmail



99+

Compose

Mail

**Inbox** 2,387

Chat

Starred

Meet

Snoozed

Sent

**Drafts** 38

More

Labels

[JBK] New notification from Jurnal Biomedika dan Kesehatan External



**Administrator Administrator** <editor@jbiomedkes.org>  
to me

You have a new notification from Jurnal Biomedika dan Kesehatan:

An issue has been published.

Link: <https://jbiomedkes.org/index.php/jbk/issue/current>

Dr. dr. Husnun Amalia, Sp.M

---

[Jurnal Biomedika dan Kesehatan](#)

Jl. Kyai Tapa No. 260 Kampus B, Grogol, DKI Jakarta 11440

Telp. (021) 5672731 | E-mail: [jbiomedkes@trisakti.ac.id](mailto:jbiomedkes@trisakti.ac.id)

Reply

Forward

## ORIGINAL ARTICLE

# Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and Hs-CRP Levels in Type 2 Diabetes Mellitus

## Kontrol Glikemik dan Penilaian Risiko Kardiovaskular: Studi Kadar HbA1c dan Hs-CRP pada Diabetes Melitus Tipe 2

Mustika Anggiane Putri<sup>1</sup>, Patwa Amani<sup>1</sup>, Donna Adriani<sup>1</sup>, Yudhisman Imran<sup>2</sup>

<sup>1</sup>Departement of Physiology, Faculty of medicine, Universitas Trisakti, Jakarta, Indonesia

<sup>2</sup>Department of Neurology, Faculty of medicine, Universitas Trisakti, Jakarta, Indonesia

[inge.mustika@trisakti.ac.id](mailto:inge.mustika@trisakti.ac.id)

<https://doi.org/10.18051/JBiomedKes.2025.v8.142-150>

### ABSTRACT

#### Background

Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease. Patients with diabetes have a 2-4 times higher risk of developing coronary heart disease compared to those without diabetes. Cardiovascular complications are the leading cause of illness and death in diabetic patients, with cardiovascular disease-related deaths making up 65-75% of all deaths in this group. Poor glycemic control is a key factor in the development of cardiovascular problems in diabetes. Chronic high blood sugar levels activate various harmful mechanisms, including increased oxidative stress, systemic inflammation, endothelial dysfunction, and faster atherosclerosis. Hemoglobin A1C (HbA1C), a marker of long-term blood sugar control, strongly correlates with the risk of both microvascular and macrovascular complications in diabetes. This study aims to examine the relationship between glycemic control, as measured by HbA1C, and systemic inflammation, assessed through Hs-CRP, as predictors of cardiovascular risk in patients with type 2 diabetes mellitus.

#### Methods

An analytical cross-sectional study was conducted on 53 T2DM patients at the Prolanis Clinic in East Jakarta, using purposive sampling. HbA1c was measured with the HPLC method, and Hs-CRP with the Turbidimetric Immunoassay method at PRODIA laboratory. Correlation analysis was performed using Spearman's correlation test.

#### Results

The study showed an average HbA1C level of 7.2% and an average Hs-CRP level of 2.9 mg/L. Statistical analysis indicated a significant correlation between HbA1C and Hs-CRP (p-value = 0.014), with a Spearman correlation coefficient of 0.336.

#### Conclusions

There is a significant positive correlation between HbA1c and Hs-CRP levels.

**Keywords:** Cardiovascular risk; HbA1C; Hs-CRP; Inflammation; Type 2 diabetes mellitus.

## ABSTRAK

### Latar Belakang

Diabetes melitus tipe 2 (T2DM) merupakan faktor risiko utama penyakit kardiovaskular. Pasien diabetes memiliki risiko 2-4 kali lebih tinggi mengalami penyakit jantung koroner dibandingkan populasi non-diabetes. Komplikasi kardiovaskular menjadi penyebab utama morbiditas dan mortalitas pada pasien diabetes, dengan angka kematian akibat penyakit kardiovaskular mencapai 65-75% dari total kematian populasi diabetes. Kontrol glikemik yang buruk menjadi faktor kunci patogenesis komplikasi kardiovaskular pada diabetes. Hiperglikemia kronis memicu berbagai mekanisme patofisiologis, termasuk peningkatan stres oksidatif, inflamasi sistemik, disfungsi endotel, dan percepatan proses aterosklerosis. Hemoglobin A1C (HbA1C) sebagai parameter kontrol glikemik jangka panjang telah terbukti berkorelasi kuat dengan risiko komplikasi mikrovaskular dan makrovaskular pada diabetes. Penelitian ini bertujuan menganalisis korelasi antara kontrol glikemik yang dinilai melalui HbA1C dengan status inflamasi sistemik yang diukur melalui Hs-CRP sebagai predictor resiko kardiovaskular pada pasien diabetes melitus tipe 2.

### Metode

Studi potong lintang analitik pada 53 pasien T2DM di Klinik Prolanis Jakarta Timur (purposive sampling). Pemeriksaan HbA1c dengan metode HPLC dan Hs-CRP dengan metode Turbidimetric Immunoassay dilakukan di laboratorium PRODIA. Korelasi dianalisis menggunakan uji korelasi Spearman.

### Hasil

pada studi ini didapatkan rerata kadar HbA1C adalah 7.2% dan rerata Hs-CRP adalah 2.9 mg/L. Analisis statistik menunjukkan korelasi signifikan antara HbA1C dan Hs-CRP (p-value = 0.014) dengan koefisien korelasi Spearman 0.336.

### Kesimpulan

Terdapat korelasi positif yang signifikan antara kadar HbA1c dan Hs-CRP.

**Kata Kunci:** Risiko Kardiovaskular; HbA1C; hsCR; Inflamasi; Diabetes melitus tipe 2.

## INTRODUCTION

The global prevalence of type 2 diabetes mellitus (T2DM) has shown a significant increase due to changes in human lifestyle patterns and behavioral modifications.<sup>1,2</sup> Diabetes has become a leading cardiometabolic disorder, affecting 10.5% of the adult population (aged 20-79 years) in 2021, with projections suggesting an increase to 12.2% by 2045.<sup>2,3</sup> The prevalence is higher in urban areas (12.1%) compared to rural regions (8.3%), and in high-income countries (11.1%) versus low-income nations (5.5%). The most notable relative rise is expected in middle-income countries (21.1%) compared to high-income (12.2%) and low-income countries (11.9%). In Indonesia, T2DM prevalence shows an alarming trend, with rates continuously rising alongside societal changes in lifestyle and diet patterns.

Diabetes mellitus goes beyond being a simple health issue; it is a major risk factor for cardiovascular disease. Diabetic patients face a 2-4 times higher risk of developing coronary heart disease compared to non-diabetic people.<sup>4</sup> Cardiovascular complications are the leading cause of illness and death in diabetic patients, with cardiovascular-related deaths making up 65-75% of all mortalities in this group.<sup>4,5</sup> Poor control of blood sugar levels plays a key role in the development of cardiovascular problems in diabetes. Chronic high blood sugar levels activate various harmful processes, including increased oxidative stress, widespread inflammation, damage to blood vessel lining, and faster buildup of plaque in arteries.<sup>1</sup> This creates a harmful cycle that speeds up the development of cardiovascular disease in diabetic patients.<sup>1,2</sup>

Hemoglobin A1c (HbA1c), a long-term indicator of glycemic control, has been shown to correlate with microvascular and macrovascular complications in diabetes.<sup>6</sup> HbA1C reflects the average blood glucose levels over the preceding 8-12 weeks and serves as the gold standard for

monitoring glycemic control in diabetic patients. The American Diabetes Association has recognized an HbA1c level of 6.5% or higher as a diagnostic threshold for diabetes and an HbA1c level of greater than 7% as indicative of poor glycemic control.<sup>6</sup> Conversely, high-sensitivity C-Reactive Protein (Hs-CRP) represents a sensitive systemic inflammatory biomarker that has been recognized as an independent predictor of cardiovascular risk. Low-grade chronic inflammation constitutes a crucial characteristic of type 2 diabetes mellitus and plays a significant role in the development of cardiovascular complications.<sup>7</sup> Elevated Hs-CRP levels in diabetic patients not only reflect systemic inflammatory status but also correlate with glycemic control levels and future cardiovascular event risk.<sup>8,9</sup> Given the concerning projected increase in diabetes prevalence, particularly in middle-income countries such as Indonesia, the identification of predictive biomarkers for cardiovascular risk becomes critically important for timely preventive interventions. Therefore, understanding the relationship between glycemic control and inflammatory status becomes essential in the comprehensive management of diabetic patients.

This study aims to analyze the correlation between glycemic control, as assessed by HbA1c, and systemic inflammatory status, as measured by Hs-CRP, in T2DM patients. Although the relationship between glycemic control and cardiovascular complications in type 2 diabetes mellitus has been extensively documented, research specifically analyzing the correlation between HbA1c and Hs-CRP as systemic inflammatory biomarkers in the Indonesian population remains limited. This study contributes novel insights into understanding the interaction between long-term glycemic control and chronic inflammatory status in T2DM patients in Indonesia, who possess distinct demographic and genetic characteristics compared to Western populations.

## METHODS

This analytical cross-sectional study was conducted among participants of the Prolanis Diabetes Clinic in East Jakarta. The total clinic population consisted of 64 individuals with type 2 diabetes mellitus (T2DM), of whom 53 subjects were included using purposive sampling. Five people were excluded due to absence during blood collection, and six people were excluded for showing Hs-CRP results greater than 10 mg/L (indicating the presence of acute systemic inflammation that could be caused by various diseases).<sup>10</sup> Eligible participants were men and women aged 40–60 years with a diagnosis of type 2 diabetes mellitus (T2DM). Exclusion criteria included any known cardiovascular, neurological, malignancy, or pulmonary diseases, as well as any current illness or history of inflammatory conditions that could affect Hs-CRP levels, such as rheumatoid arthritis, gout, or infections.

To justify the sample size, a power estimation was conducted based on the correlation coefficient ( $r = 0.81$ ) reported in a previous study by Reddy et al. (2024)<sup>6</sup>, which found a strong positive relationship between HbA1c and Hs-CRP levels in patients with T2DM and myocardial infarction. Assuming a significance level of 0.05 and statistical power of 80% ( $\beta = 0.20$ ), the minimum number of subjects required to detect a statistically significant correlation of similar strength would be considerably less than the 53 subjects included in this study. Therefore, the chosen sample size was considered statistically adequate and appropriate for the study objective.

Venous blood samples were collected and processed by the certified PRODIA Laboratory for HbA1c and Hs-CRP. Hemoglobin A1c was measured using HPLC, standardized under the National Glycohemoglobin Standardization Program (NGSP), with the Tina-quant HbA1c kit on the Cobas Integra analyzer, serving as a marker of long-term glycemic control. Hs-CRP levels were determined using a validated turbidimetric immunoassay method with i-CHROMA™ hsCRP-ALL in one kit (Boditech Med Inc.) to assess systemic inflammation and cardiovascular risk.

The study protocol was reviewed and approved by the Ethics Committee of the Faculty of Medicine, Trisakti University (No.055/KER/FK/II/2023). Descriptive statistics were used to evaluate

demographic and clinical characteristics, with means and standard deviations for continuous variables and percentages for categorical data. The correlation between HbA1c and Hs-CRP was analyzed using Spearman's rank correlation test. Data analysis was conducted with SPSS software.

## RESULTS

The distribution of subject characteristics based on gender, age, blood pressure, HbA1C levels, and Hs-CRP is presented in Table 1. This study involved 53 subjects with type 2 diabetes mellitus (T2DM), comprising 36 females (67.9%) and 17 males (32.1%). The age distribution revealed that the majority of subjects were within the 40-60 years age range, accounting for 40 individuals (75.5%), while 13 subjects (24.5%) were aged 60 years or older.

**Table 1.** Distribution of Subject Characteristics

Variable	Frequency	min	max	mean±SD
<b>Gender</b>				
Men	17 (32.1%)			
Women	36 (67.9%)			
<b>Age (year)</b>				
40 – 60	40 (75.5%)			
>60	13 (24.5%)			
<b>Inflammation risk categories</b>				
Low risk (< 1.0 mg/L)	8 (15.1%)			
Intermediate risk ( 1.0 – 3.0 mg/L)	28 (52.8%)			
High risk (>3.0 mg/L)	17 (32.1%)			
<b>Tekanan Darah</b>				
Sistolik (mmHg)		100	202	138.2 ± 19.6
Diastolik (mmHg)		70	115	87.7 ± 9.2
<b>Serum Level</b>				
HbA1c (%)		4.8	11.3	7.2 ± 1.8
Hs-CRP (mg/L)		0.3	9.7	2.9 ± 2.4

The mean systolic and diastolic blood pressure values in this study were 138.2 mmHg and 87.7 mmHg, respectively. The mean HbA1C level among subjects was 7.2%, indicating poor glycemic control. The study results showed a mean Hs-CRP level of 2.9 mg/dL, indicating an intermediate risk. Cardiovascular risk assessment using Hs-CRP levels according to American Heart Association criteria revealed that 8 participants (15.1%) had low risk (Hs-CRP <1 mg/L), 28 participants (52.8%) had intermediate risk (Hs-CRP 1.0-3.0 mg/L), and 17 participants (32.1%) had high risk (Hs-CRP >3 mg/L).<sup>11</sup>

**Table 2.** Correlation Analysis Between HbA1C, Blood Pressure and Hs-CRP

Variable		Hs-CRP
HbA1C	spearman Correlation	.336**
	Sig.(2-tailed)	.014*
Systolic blood pressure	spearman Correlation	.277**
	Sig.(2-tailed)	.044*
Diastolic blood pressure	spearman Correlation	.059
	Sig.(2-tailed)	.673

### Spearman

\*Correlation is significant at the 0.05 level (2-tailed)

\*\*Correlation is significant at the 0.01 level (2-tailed)

A non-parametric Spearman correlation analysis was performed to assess the relationship between glycemic control parameters, hemodynamic variables, and Hs-CRP as a predictor of cardiovascular risk among 53 patients with T2DM. The results are shown in Table 2. The analysis found a statistically significant positive correlation between HbA1c levels and Hs-CRP concentrations ( $r = 0.336$ ,  $p = 0.014$ ). This indicates that higher HbA1c levels are linked with increased Hs-CRP levels, implying a connection between poor glycemic control and cardiovascular risk in diabetic patients.

Regarding hemodynamic parameters, systolic blood pressure demonstrated a significant positive correlation with Hs-CRP levels ( $r = 0.277$ ,  $p = 0.044$ ). This finding suggests that elevated systolic blood pressure is associated with increased inflammatory markers, potentially indicating the role of hypertension in cardiovascular risk enhancement through inflammatory pathways. Conversely, diastolic blood pressure showed no significant correlation with Hs-CRP levels ( $r = 0.059$ ,  $p = 0.673$ ).

## DISCUSSION

Based on the research data presented in Table 2, a distinct pattern of relationship exists between Hs-CRP and the components of systolic and diastolic blood pressure. The Spearman correlation analysis revealed a significant relationship between Hs-CRP and systolic blood pressure ( $r = 0.277$ ,  $p = 0.044$ ); however, no significant relationship was found with diastolic blood pressure ( $r = 0.059$ ,  $p = 0.673$ ). This finding offers an interesting insight into the interaction between systemic inflammatory markers and cardiovascular hemodynamic parameters in patients with type 2 diabetes mellitus.<sup>8,9</sup> Previous studies have established the relationship between diabetes and the occurrence of hypertension.<sup>12</sup> Diabetes and hypertension can increase each other, and when they occur together, they significantly elevate the risk of cardiovascular disease.<sup>12-14</sup>

Hs-CRP is an inflammatory marker produced by the liver and elevated during inflammation, including the process of atherosclerosis, and has been proven to be a marker that can predict cardiovascular disease risk.<sup>6</sup> This study demonstrated a significant relationship between systolic blood pressure and Hs-CRP but not with diastolic blood pressure. This phenomenon can occur because systolic blood pressure is more sensitive to vascular inflammatory changes compared to diastolic pressure, as systolic pressure reflects the strength of cardiac contraction and the elasticity of larger arterial blood vessels.<sup>15</sup> When chronic inflammation occurs, as indicated by increased Hs-CRP, arterial walls become stiffer and less elastic, which directly affects systolic pressure.<sup>15</sup> Conversely, diastolic pressure more reflects the resistance of smaller peripheral blood vessels and is not significantly influenced by inflammatory processes occurring in larger blood vessels.<sup>14</sup> Poor glycemic conditions trigger systemic inflammation that increases Hs-CRP.<sup>1,2,6</sup> This inflammation contributes to arterial stiffening, which has a greater impact on the systolic component of blood pressure.<sup>15</sup> Therefore, Hs-CRP as a predictor of cardiovascular inflammation demonstrates a stronger correlation with systolic pressure because both reflect vascular damage occurring in major arterial blood vessels, while diastolic pressure remains more stable and is not significantly affected by systemic inflammatory changes measured through Hs-CRP.<sup>15-16</sup>

High blood pressure (hypertension) and diabetes frequently occur simultaneously and increase the risk of cardiovascular disease. Elevated blood glucose levels and high blood pressure can damage the vascular endothelium, subsequently leading to the formation of atherosclerosis.<sup>4</sup>

<sup>5</sup> The fundamental concept of atherosclerosis is arterial hardening due to the gradual accumulation of fatty plaques within the vessel walls. This plaque accumulation restricts blood flow.<sup>4</sup>

Atherosclerosis begins with endothelial activation, followed by a cascade of events such as lipid accumulation and fibrous proliferation.<sup>5</sup> Non-enzymatic glycation reactions between glucose and proteins or lipoproteins in arterial walls are one of the key mechanisms responsible for the accelerated formation of atherosclerosis under hyperglycemic conditions in type 2 diabetes mellitus.<sup>15</sup> Prolonged exposure to hyperglycemia is believed to be a primary factor in the development of atherosclerosis in diabetes. Hyperglycemia causes numerous changes at the cellular level of vascular tissue that can potentially speed up the atherosclerotic process.<sup>17-18</sup>

Another important biochemical process accompanying type 2 diabetes mellitus is the formation of Advanced Glycation End Products (AGEs). These AGEs likely also underlie the general inflammatory process.<sup>19</sup> The formation and accumulation of AGEs are associated with aging processes and are accelerated in diabetes.<sup>20</sup> AGEs are produced under hyperglycemic conditions, but their production also occurs in situations characterized by oxidative stress and inflammation.<sup>18</sup> Activation of AGE receptors can induce cascading inflammatory responses that cause increased inflammation, oxidative stress, enhanced calcium deposition, and increased vascular smooth muscle apoptosis. This contributes to the development of atherosclerosis.<sup>21</sup>

The synergistic reaction between hypertension and hyperglycemia causes atherosclerosis formation through at least two mechanisms: elevated hemodynamic pressure in hypertensive conditions damages the endothelium and upregulates the renin-angiotensin-aldosterone system, oxidative stress, and inflammation, which contribute to the close relationship between diabetes and hypertension.<sup>22</sup>

High-sensitivity C-reactive protein (Hs-CRP) is a systemic inflammatory marker that emerges as an independent risk factor for cardiovascular disease.<sup>23-24</sup> Elevated Hs-CRP levels are associated with increased risk of thrombotic events, including myocardial infarction. Increased Hs-CRP levels are also associated with increased risk of developing diabetes later in life. Furthermore, it has been found that Hs-CRP levels are higher in diabetic patients compared to those without diabetes.<sup>25-27</sup> This study demonstrated a significant relationship between Hs-CRP and HbA1c. This finding is consistent with studies conducted by Seo HY, Khairinisa G, and Reddy KSS, which reported that HbA1c levels increased significantly with increasing Hs-CRP levels.<sup>6,7</sup> In contrast to the study conducted by Sari EP (2023), which stated that her study results showed no significant correlation between HbA1c levels and CRP (p-value=0.171 and r=0.218).<sup>8</sup> The key differences between this study and Sari EP (2023) involve measurement sensitivity and sample size. Sari used a semi-quantitative latex agglutination method for CRP with a detection threshold of 0.6 mg/dL (6 mg/L), which is less sensitive for detecting low-grade inflammation compared to our validated turbidimetric immunoassay capable of measuring Hs-CRP below 0.1 mg/L. Hs-CRP's superior sensitivity allows identification of subtle inflammatory changes specifically relevant to cardiovascular risk assessment. The sample size difference is also crucial; Sari's 24 subjects versus our 53 participants significantly affect statistical power to detect associations.<sup>8</sup>

Hs-CRP directly participates in the pathogenesis of atherosclerosis by inducing inflammation in endothelial cells and coronary arterial smooth muscle cells. Hs-CRP levels in various morbidity and mortality assessments are considered one of the factors taken into account and are added to the Framingham score as predictor factors, enhancing cardiovascular risk prediction. While this study identified a statistically significant correlation between HbA1c and Hs-CRP, potential confounding factors must be acknowledged. Variables such as BMI, lipid profile, and medications—particularly statins, anti-inflammatory agents, and metformin—are known to influence systemic inflammation. Previous studies have demonstrated that metformin reduces Hs-

CRP levels by suppressing the secretion of proinflammatory cytokines in hepatocytes and macrophages, indicating anti-inflammatory properties beyond glucose control.<sup>28</sup> However, due to data limitations, these variables were not adjusted for in the current analysis. Future studies incorporating multivariable regression models are warranted to control for confounding variables and clarify the independent relationship between glycemic control and systemic inflammation.

## CONCLUSION

This study shows a strong positive link between HbA1c and Hs-CRP levels in T2DM, indicating that poor blood sugar control is connected to increased systemic inflammation. Additionally, Hs-CRP has a significant relationship with systolic blood pressure but not with diastolic blood pressure, implying that inflammatory markers mainly influence arterial stiffness and larger vessel function. These results support using Hs-CRP as an important biomarker for assessing cardiovascular risk in diabetic patients, especially when combined with measures of glycemic control.

## ACKNOWLEDGEMENT

The authors would like to express their sincere gratitude to all research team members who contributed to the successful completion of this study. We also acknowledge the support provided by the participants and the medical staff who facilitated data collection.

## AUTHORS CONTRIBUTION

The concept, analysis, and interpretation of data, drafting manuscript: Putri MA. Collecting data, assisted in developing research methodology: MAP, PA, DA, YI. Critical review of the manuscript: PA, DA, YI.

## FUNDING

This research was supported by an internal grant from Universitas Trisakti.

## CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose.

## REFERENCES

1. Gudisa B, Gemechis B. The incidence and predictors of poor glycemic control among adults with type 2 diabetes mellitus in ambulatory clinic of Mettu Karl Referral Hospital, South Western, Ethiopia: a prospective cross sectional study. *Int Arch Endocrinol Clin Res.* 2021;7(1). DOI: 10.23937/2572-407X.1510024.
2. Rosengren A, Dikaïou P. Cardiovascular outcomes in type 1 and type 2 diabetes. *Diabetologia.* 2023;66:425–37. DOI: 10.1007/s00125-022-05857-5.
3. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract.* 2022;183:109-19. DOI: 10.1016/j.diabres.2021.109119.
4. Verma S, Leiter LA. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. *Can J Cardiol.* 2018;34(5):575–84. DOI: 10.1016/j.cjca.2017.12.005.
5. Rodriguez-Araujo G, Nakagami H. Pathophysiology of cardiovascular disease in diabetes mellitus. *Cardiovasc Endocrinol Metab.* 2018;7(1):4–9. DOI: 10.1097/XCE.0000000000000141.

6. Reddy KSS, Varadaraj P, Nallusamy G, et al. Correlation between hemoglobin A1c (HbA1c) and high-sensitivity C-reactive protein (Hs-CRP) in myocardial infarction patients and their six-month mortality follow-up. *Cureus*. 2024;16(8):e67070. DOI: 10.7759/cureus.67070.
7. Seo YH, Shin HY. Relationship between Hs-CRP and HbA1c in diabetes mellitus patients: 2015–2017 Korean National Health and Nutrition Examination Survey. *Chonnam Med J*. 2021;57(1):62–8. DOI: 10.4068/cmj.2021.57.1.62.
8. Sari EP, Sayekti S. Korelasi kadar HbA1c dengan C-reactive protein pasien diabetes melitus tipe 2. *Jurnal Sintesis Penelitian Sains Terapan dan Analisisnya*. 2023;4(1):1–7. DOI: 10.56399/jst.v4i1.102.
9. Venkatamani Y, Raj JR, Ahmed MI, et al. Study of C-reactive protein, D-dimer in correlation with HbA1c levels in patients with diabetes mellitus type 2. *Panacea J Med Sci*. 2023;13(1):72–7. DOI: 10.18231/j.pjms.2023.016.
10. Wolska A, Remaley AT. CRP and High-Sensitivity CRP: "What's in a Name?". *J Appl Lab Med*. 2022;7(6):1255–8. DOI: <https://doi.org/10.1093/jalm/jfac076>
11. Johns I, Moschonas KE, Medina J, et al. Risk classification in primary prevention of CVD according to QRISK2 and JBS3 'heart age', and prevalence of elevated high-sensitivity C-reactive protein in the UK cohort of the EURIKA study. *Open Heart*. 2018;5:e000849. DOI: 10.1136/openhrt-2018-000849
12. Wang B, Yang Y, Li X. Interaction of hypertension and insulin resistance exacerbates the occurrence of diabetes mellitus in healthy individuals. *J Diabetes Res*. 2022;2022:1–8. DOI: 10.1155/2022/1234567.
13. Midha T. Correlation between hypertension and hyperglycemia among young adults in India. *World J Clin Cases*. 2015;3(2):171–6. DOI: 10.12998/wjcc.v3.i2.171.
14. Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, et al. Hypertension and diabetes mellitus coprediction and time trajectories. *Hypertension*. 2018;71(3):422–8. DOI: 10.1161/HYPERTENSIONAHA.117.10546.
15. Kim HL. Arterial stiffness and hypertension. *Clin Hypertens*. 2023;29(1):31. DOI: 10.1186/s40885-023-00258-1.
16. Kandil H, Soliman A, Alghamdi NS, et al. Using mean arterial pressure in hypertension diagnosis versus using either systolic or diastolic blood pressure measurements. *Biomedicines*. 2023;11(3):849. DOI: 10.3390/biomedicines11030849.
17. Geraghty L, Wood MJ. Cardiovascular disease in women: from pathophysiology to novel and emerging risk factors. *Heart Lung Circ*. 2021;30(1):9–17. DOI:10.1016/j.hlc.2020.05.108.
18. Schmidt AM. Diabetes mellitus and cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2019;39(4):558–66. DOI: 10.1161/ATVBAHA.119.310961.
19. Lee J, Yun JS, Ko SH. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. *Nutrients*. 2022;14(15):3086. DOI: 10.3390/nu14153086.
20. Mao L, Yin R, Yang L, et al. Role of advanced glycation end products on vascular smooth muscle cells under diabetic atherosclerosis. *Front Endocrinol (Lausanne)*. 2022;13:983723. DOI: 10.3389/fendo.2022.983723.
21. Putri MA, Amani P, Adriani D, et al. Importance of exercise in mitigating age-related cardiac apoptosis. *Sriwijaya Journal of Medicine*. 2023;6(3):94–101. DOI: 10.32539/sjm.v6i3.208.
22. Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. *Circ Res*. 2020;126(11):1501–25. DOI: 10.1161/CIRCRESAHA.120.315913.
23. Dayoub A, Khayat MI, Zrieki A. Association of high sensitivity C-reactive protein (Hs-CRP) with poor glycaemic control and coronary heart disease in type 2 diabetes mellitus. *Res J Pharm Technol*. 2023;16(1):193–9. DOI: 10.52711/0974-360X.2023.00036.
24. Sasidharan A, Krishnamurthy A, Tagore S, et al. C-reactive protein and glycaemic control in adults with type 2 diabetes mellitus. *J Med Radiol Pathol Surg*. 2016;2(1):1–4. DOI: 10.15713/ins.jmrps.56.
25. He P, Fan SY, Guan JQ, et al. Mediation analysis for the relationship between dyslipidemia and coronary artery disease via hypersensitive C-reactive protein in a case-control study. *Coron Artery Dis*. 2020;31(7):613–9. DOI: 10.1097/MCA.0000000000000911.
26. Patil V, Avhad A, Kulkarni A, et al. High-sensitive C-reactive protein in patients with coronary artery disease. *J Nat Sci Biol Med*. 2020;11(1):39–44. DOI: 10.4103/jnsbm.JNSBM\_159\_19.
27. Indrajaya T, Saleh MI, Miliyandra M. The role of high-sensitivity C-reactive protein serum in assessing troponin T in acute myocardial infarction. *Open Access Maced J Med Sci*. 2020;8(B):1053–6. DOI: 10.3889/oamjms.2020.5495.

28. Karbalaee-Hasani A, Khadive T, Eskandari M, et al. Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Ann Pharmacother.* 2021;55(9):1096–109. DOI: 10.1177/1060028020985303.



This work is licensed under a Creative Commons Attribution Non-Commercial 4.0 International License

---

# Mustika Anggiani Putri FK

## Glycemic Control and Cardiovascular Risk Assessment A Study on HbA1c and HsCRP Levels in Type 2 Diabetes Mellitus

Artikel Jurnal 1

---

### Document Details

Submission ID

trn:oid::3618:124789171

Submission Date

Dec 18, 2025, 8:02 PM GMT+7

Download Date

Dec 19, 2025, 10:15 AM GMT+7

File Name

Glycemic Control and Cardiovascular Risk Assessment A Study on HbA1c and HsCRP Levels in Ty....docx

File Size

112.9 KB

10 Pages

3,753 Words

24,472 Characters

# 18% Overall Similarity

The combined total of all matches, including overlapping sources, for each database.

## Filtered from the Report

- ▶ Bibliography
- ▶ Quoted Text
- ▶ Small Matches (less than 10 words)

## Exclusions

- ▶ 4 Excluded Matches

## Match Groups

- 32 Not Cited or Quoted 14%**  
Matches with neither in-text citation nor quotation marks
- 10 Missing Quotations 4%**  
Matches that are still very similar to source material
- 0 Missing Citation 0%**  
Matches that have quotation marks, but no in-text citation
- 0 Cited and Quoted 0%**  
Matches with in-text citation present, but no quotation marks

## Top Sources

- 15% Internet sources
- 10% Publications
- 0% Submitted works (Student Papers)

## Integrity Flags

0 Integrity Flags for Review

Our system's algorithms look deeply at a document for any inconsistencies that would set it apart from a normal submission. If we notice something strange, we flag it for you to review.

A Flag is not necessarily an indicator of a problem. However, we'd recommend you focus your attention there for further review.

### Match Groups

- **32 Not Cited or Quoted** 14%  
Matches with neither in-text citation nor quotation marks
- **10 Missing Quotations** 4%  
Matches that are still very similar to source material
- **0 Missing Citation** 0%  
Matches that have quotation marks, but no in-text citation
- **0 Cited and Quoted** 0%  
Matches with in-text citation present, but no quotation marks

### Top Sources

- 15% Internet sources
- 10% Publications
- 0% Submitted works (Student Papers)

### Top Sources

The sources with the highest number of matches within the submission. Overlapping sources will not be displayed.

1	Internet	pmc.ncbi.nlm.nih.gov	2%
2	Internet	www.frontiersin.org	2%
3	Internet	jbiomedkes.org	2%
4	Internet	mdpi-res.com	<1%
5	Internet	pure.uva.nl	<1%
6	Publication	Alina-Ioana Forray, Laura Gavrilaş, Anca-Elena Crăciun, Cristina Maria Borzan. "C...	<1%
7	Internet	www.science.gov	<1%
8	Internet	pubs.acs.org	<1%
9	Internet	www.mdpi.com	<1%
10	Publication	M. Wang, K. Huang, Yinzi Jin, Z.-J. Zheng. "Global Burden of Alzheimer's Disease a...	<1%

11	Internet	topsecretapiaccess.dovepress.com	<1%
12	Publication	Elif Ijlal Cekirdekci, Baris Bugan. "Whole blood viscosity in microvascular angina a...	<1%
13	Internet	pure.umcutrecht.nl	<1%
14	Internet	www.hilarispublisher.com	<1%
15	Publication	Farah Adelia Qotrunnada, Anik Handayati, Museyaroh, Lully Hanni Endarini. "Co...	<1%
16	Internet	academic.oup.com	<1%
17	Internet	dokumen.pub	<1%
18	Internet	www.jptcp.com	<1%
19	Publication	Fuyu Wang, Yating Li, Lan Bai, Wenjing Xiao, Ling Zhong, Jianyou Shi. "Advances i...	<1%
20	Internet	bmcresnotes.biomedcentral.com	<1%
21	Internet	kesehatanvegan.com	<1%
22	Internet	repositorio.bc.ufg.br	<1%
23	Publication	Hurriyati Ratih, Tjahjono Benny, GafarAbdullah Ade, Sulastri, Lisnawati. "Advance...	<1%
24	Publication	Michael Dall, Ove B. Schaffalitzky de Muckadell, Jane Møller Hansen, Mette Wildn...	<1%

25	Internet	ejournal3.undip.ac.id	<1%
26	Internet	jurnal.iptlmi-iasmlt.id	<1%
27	Internet	link.springer.com	<1%
28	Internet	www.dovepress.com	<1%
29	Internet	www.ijsr.net	<1%

## ORIGINAL ARTICLE

# Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and Hs-CRP Levels in Type 2 Diabetes Mellitus

## Kontrol Glikemik dan Penilaian Risiko Kardiovaskular: Studi Kadar HbA1c dan Hs-CRP pada Diabetes Melitus Tipe 2

Mustika Anggiane Putri<sup>1</sup>, Patwa Amani<sup>1</sup>, Donna Adriani<sup>1</sup>, Yudhisman Imran<sup>2</sup>

<sup>1</sup> Departement of Physiology, Faculty of medicine, Universitas Trisakti, Jakarta, Indonesia

<sup>2</sup> Department of Neurology, Faculty of medicine, Universitas Trisakti, Jakarta, Indonesia

✉ [inge.mustika@trisakti.ac.id](mailto:inge.mustika@trisakti.ac.id) (Correspondence email)

<https://doi.org/10.56186/jkkb.xxx>

### ABSTRACT

#### Background:

Type 2 diabetes mellitus (T2DM) represents a major risk factor for cardiovascular disease. Diabetic patients have a 2-4 fold higher risk of developing coronary heart disease compared to the non-diabetic population. Cardiovascular complications constitute the leading cause of morbidity and mortality in diabetic patients, with cardiovascular disease-related deaths accounting for 65-75% of total mortality in the diabetic population. Poor glycemic control serves as a key factor in the pathogenesis of cardiovascular complications in diabetes. Chronic hyperglycemia triggers various pathophysiological mechanisms, including increased oxidative stress, systemic inflammation, endothelial dysfunction, and accelerated atherosclerotic processes. Hemoglobin A1C (HbA1C) as a parameter of long-term glycemic control has been proven to strongly correlate with the risk of microvascular and macrovascular complications in diabetes. This study aims to analyze the correlation between glycemic control assessed through HbA1C and systemic inflammatory status measured through Hs-CRP as a predictor of cardiovascular risk in patients with type 2 diabetes mellitus.

#### Methods:

An analytical cross-sectional study on 53 T2DM patients at the Prolanis Clinic in East Jakarta (purposive sampling). HbA1c examination using the HPLC method and Hs-CRP using the Turbidimetric Immunoassay method were conducted at PRODIA laboratory. Correlation was analyzed using Spearman's correlation test.

#### Results:

The study revealed a mean HbA1C level of 7.2% and a mean Hs-CRP level of 2.9 mg/L. Statistical analysis demonstrated a significant correlation between HbA1C and Hs-CRP (p-value = 0.014) with a Spearman correlation coefficient of 0.336.

**Conclusion:** There is a significant positive correlation between HbA1c and Hs-CRP levels.

**Keywords:** Cardiovascular risk; type 2 diabetes mellitus; HbA1C; Hs-CRP; inflammation

## ABSTRAK

### Latar Belakang:

Diabetes melitus tipe 2 (T2DM) merupakan faktor risiko utama penyakit kardiovaskular. Pasien diabetes memiliki risiko 2-4 kali lebih tinggi mengalami penyakit jantung koroner dibandingkan populasi non-diabetes. Komplikasi kardiovaskular menjadi penyebab utama morbiditas dan mortalitas pada pasien diabetes, dengan angka kematian akibat penyakit kardiovaskular mencapai 65-75% dari total kematian populasi diabetes. Kontrol glikemik yang buruk menjadi faktor kunci patogenesis komplikasi kardiovaskular pada diabetes. Hiperglikemia kronis memicu berbagai mekanisme patofisiologis, termasuk peningkatan stres oksidatif, inflamasi sistemik, disfungsi endotel, dan percepatan proses aterosklerosis. Hemoglobin A1C (HbA1C) sebagai parameter kontrol glikemik jangka panjang telah terbukti berkorelasi kuat dengan risiko komplikasi mikrovaskular dan makrovaskular pada diabetes. Penelitian ini bertujuan menganalisis korelasi antara kontrol glikemik yang dinilai melalui HbA1C dengan status inflamasi sistemik yang diukur melalui Hs-CRP sebagai predictor resiko kardiovaskular pada pasien diabetes melitus tipe 2.

**Metode:** Studi potong lintang analitik pada 53 pasien T2DM di Klinik Prolanis Jakarta Timur (purposive sampling). Pemeriksaan HbA1c dengan metode HPLC dan Hs-CRP dengan metode Turbidimetric Immunoassay dilakukan di laboratorium PRODIA. Korelasi dianalisis menggunakan uji korelasi Spearman.

**Hasil:** pada studi ini didapatkan rerata kadar HbA1C adalah 7.2% dan rerata Hs-CRP adalah 2.9 mg/L. Analisis statistik menunjukkan korelasi signifikan antara HbA1C dan Hs-CRP ( $p$ -value = 0.014) dengan koefisien korelasi Spearman 0.336.

**Kesimpulan:** Terdapat korelasi positif yang signifikan antara kadar HbA1c dan Hs-CRP

**Kata kunci:** Diabetes melitus tipe 2; HbA1C; hsCR; inflamasi

## INTRODUCTION

The global prevalence of type 2 diabetes mellitus (T2DM) has demonstrated a significant escalation attributable to alterations in human lifestyle patterns and behavioral modifications.<sup>1,2</sup> Diabetes has emerged as a predominant cardiometabolic disorder, affecting 10.5% of the adult population (aged 20-79 years) in 2021, with projections indicating an increase to 12.2% by 2045.<sup>2,3</sup> The prevalence exhibits higher rates in urban areas (12.1%) compared to rural regions (8.3%), and in high-income countries (11.1%) versus low-income nations (5.5%). The most substantial relative increase is projected to occur more frequently in middle-income countries (21.1%) than in high-income (12.2%) and low-income countries (11.9%), including Indonesia, T2DM prevalence demonstrates an alarming trend, with continuously rising incidence rates paralleling societal changes in lifestyle and dietary patterns.<sup>1</sup>

Diabetes mellitus extends beyond an isolated health concern, constituting a principal risk factor for cardiovascular disease. Diabetic patients exhibit a 2-4 fold elevated risk of developing coronary heart disease compared to non-diabetic populations.<sup>4</sup> Cardiovascular complications represent the primary cause of morbidity and mortality in diabetic patients, with cardiovascular-related deaths accounting for 65-75% of total mortality in the diabetic population.<sup>4,5</sup> Poor glycemic control serves as a pivotal factor in the pathogenesis of cardiovascular complications in diabetes. Chronic hyperglycemia triggers various pathophysiological mechanisms, including enhanced oxidative stress, systemic inflammation, endothelial dysfunction, and accelerated atherosclerosis.<sup>1</sup>

This condition creates a vicious cycle that accelerates the progression of cardiovascular disease in diabetic patients.<sup>1,2</sup>

Hemoglobin A1C (HbA1C), as a long-term glycemic control parameter, has been demonstrated to correlate with microvascular and macrovascular complications in diabetes.<sup>6</sup> HbA1C reflects the average blood glucose levels over the preceding 8-12 weeks and serves as the gold standard for monitoring glycemic control in diabetic patients. The American Diabetes Association has recognized an HbA1c level of 6.5% or higher as a diagnostic threshold for diabetes and an HbA1c level of >7% as a poor glycemic control.<sup>6</sup> Conversely, high-sensitivity C-Reactive Protein (Hs-CRP) represents a sensitive systemic inflammatory biomarker that has been recognized as an independent predictor of cardiovascular risk. Low-grade chronic inflammation constitutes a crucial characteristic of type 2 diabetes mellitus and plays a significant role in the development of cardiovascular complications.<sup>7</sup> Elevated Hs-CRP levels in diabetic patients not only reflect systemic inflammatory status but also correlate with glycemic control levels and future cardiovascular event risk.<sup>8,9</sup> Given the concerning projected increase in diabetes prevalence, particularly in middle-income countries such as Indonesia, the identification of predictive biomarkers for cardiovascular risk becomes critically important for timely preventive interventions. Therefore, understanding the relationship between glycemic control and inflammatory status becomes essential in the comprehensive management of diabetic patients.

This study aims to analyze the correlation between glycemic control assessed through HbA1C and systemic inflammatory status measured through Hs-CRP in T2DM patients. Although the relationship between glycemic control and cardiovascular complications in type 2 diabetes mellitus has been extensively documented, research specifically analyzing the correlation between HbA1C and Hs-CRP as systemic inflammatory biomarkers in the Indonesian population remains limited. This study contributes novel insights into understanding the interaction between long-term glycemic control and chronic inflammatory status in T2DM patients in Indonesia, who possess distinct demographic and genetic characteristics compared to Western populations.

## METHODS

This analytical cross-sectional study was conducted among participants of the Prolanis Diabetes Clinic in East Jakarta. The total clinic population consisted of 64 individuals with T2DM, of whom 53 subjects were included using purposive sampling. Five people were excluded due to absence during blood collection, and 6 people were excluded for showing Hs-CRP results > 10 mg/L (indicating the presence of acute systemic inflammation that could be caused by various diseases).<sup>10</sup> Eligible participants were men and women aged 40–60 years with a diagnosis of T2DM. Exclusion criteria included any known cardiovascular, neurological, malignancy, or pulmonary diseases, as well as any current illness or history of inflammatory conditions that could affect Hs-CRP levels, such as rheumatoid arthritis, gout, or infections.

To justify the sample size, a power estimation was conducted based on the correlation coefficient ( $r = 0.81$ ) reported in a previous study by Reddy et al. (2024)<sup>6</sup>, which found a strong positive relationship between HbA1c and Hs-CRP levels in patients with T2DM and myocardial infarction. Assuming a significance level of 0.05 and statistical power of 80% ( $\beta = 0.20$ ), the minimum

number of subjects required to detect a statistically significant correlation of similar strength would be considerably less than the 53 subjects included in this study. Therefore, the chosen sample size was considered statistically adequate and appropriate for the study objective.

Venous blood samples were collected and processed by the certified PRODIA Laboratory for HbA1c and Hs-CRP. HbA1c were measured using HPLC standardized under the National Glycohemoglobin Standardization Program (NGSP) with Tina-quant HbA1c kit on Cobas Integra analyzer, serving as a marker of long-term glycemic control. Hs-CRP levels were determined using a validated turbidimetric immunoassay method with i-CHROMA™ hsCRP-ALL in one kit (Boditech Med Inc) to assess systemic inflammation and cardiovascular risk.

The study protocol was reviewed and approved by the Ethics Committee of the Faculty of Medicine, Trisakti University (No.055/KER/FK/II/2023). Descriptive statistics were used for demographic and clinical characteristics, with means and standard deviations for continuous variables and percentages for categorical data. The correlation between HbA1c and Hs-CRP was analyzed using Spearman's rank correlation test. Data analysis was performed using SPSS software.

## RESULTS

The distribution of subject characteristics based on gender, age, blood pressure, HbA1C levels, and Hs-CRP is presented in Table 1. This study involved 53 subjects with T2DM, comprising 36 females (67.9%) and 17 males (32.1%). The age distribution revealed that the majority of subjects were within the 40-60 years age range, accounting for 40 individuals (75.5%), while 13 subjects (24.5%) were aged >60 years.

The mean systolic and diastolic blood pressure values in this study demonstrated a mean systolic blood pressure of 138.2 mmHg and a diastolic blood pressure of 87.7 mmHg. The mean HbA1C level among subjects was 7.2%, indicating poor glycemic control. The study results showed a mean Hs-CRP level of 2.9 mg/dL, indicating an intermediate risk. Cardiovascular risk assessment using Hs-CRP levels according to American Heart Association criteria revealed that 8 participants (15.1%) had low risk (Hs-CRP <1 mg/L), 28 participants (52.8%) had intermediate risk (Hs-CRP 1.0-3.0 mg/L), and 17 participants (32.1%) had high risk (Hs-CRP >3 mg/L).<sup>11</sup>

A non-parametric Spearman correlation analysis was conducted to examine the correlation between glycemic control parameters, hemodynamic variables, and Hs-CRP as a cardiovascular risk predictor among 53 patients with T2DM. The results of the correlation analysis are presented in Table 2. The analysis revealed a statistically significant positive correlation between HbA1c levels and Hs-CRP concentrations ( $r = 0.336$ ,  $p = 0.014$ ). This correlation indicates that elevated HbA1c levels are associated with increased Hs-CRP levels, suggesting a correlation between poor glycemic control and cardiovascular risk in diabetic patients.

Regarding hemodynamic parameters, systolic blood pressure demonstrated a significant positive correlation with Hs-CRP levels ( $r = 0.277$ ,  $p = 0.044$ ). This finding suggests that elevated systolic blood pressure is associated with increased inflammatory markers, potentially indicating the role of hypertension in cardiovascular risk enhancement through inflammatory pathways. Conversely, diastolic blood pressure showed no significant correlation with Hs-CRP levels ( $r = 0.059$ ,  $p = 0.673$ ).

## DISCUSSIONS

12  
7  
Based on the research data presented in Table 2, there is a distinct pattern of relationship between Hs-CRP and the components of systolic and diastolic blood pressure. The Spearman correlation analysis revealed a significant relationship between Hs-CRP and systolic blood pressure ( $r = 0.277$ ,  $p = 0.044$ ); however, no significant relationship was found with diastolic blood pressure ( $r = 0.059$ ,  $p = 0.673$ ). This finding provides an interesting insight into how systemic inflammatory markers interact with cardiovascular hemodynamic parameters in patients with type 2 diabetes mellitus.<sup>8,9</sup> Previous studies have established the relationship between diabetes and the occurrence of hypertension.<sup>12</sup> Diabetes and hypertension can increase the risk of each other, and when they occur together, they significantly elevate the risk of cardiovascular disease.<sup>12-14</sup>

Hs-CRP is an inflammatory marker produced by the liver and elevated during inflammation, including in the process of atherosclerosis, and has been proven as a marker that can predict cardiovascular disease risk.<sup>6</sup> This study demonstrated a significant relationship between systolic blood pressure and Hs-CRP but not with diastolic blood pressure. This phenomenon can occur because systolic blood pressure is more sensitive to vascular inflammatory changes compared to diastolic pressure, as systolic pressure reflects the strength of cardiac contraction and the elasticity of larger arterial blood vessels.<sup>15</sup> When chronic inflammation occurs, as indicated by increased Hs-CRP, arterial walls become stiffer and less elastic, which directly affects systolic pressure.<sup>15</sup> Conversely, diastolic pressure more reflects the resistance of smaller peripheral blood vessels and is not significantly influenced by inflammatory processes occurring in larger blood vessels.<sup>14</sup> Poor glycemic conditions trigger systemic inflammation that increases Hs-CRP.<sup>1,2,6</sup> This inflammation contributes to arterial stiffening, which has a greater impact on the systolic component of blood pressure.<sup>15</sup> Therefore, Hs-CRP as a predictor of cardiovascular inflammation demonstrates a stronger correlation with systolic pressure because both reflect vascular damage occurring in major arterial blood vessels, while diastolic pressure remains more stable and is not significantly affected by systemic inflammatory changes measured through Hs-CRP.<sup>15-16</sup>

High blood pressure (hypertension) and diabetes frequently occur simultaneously and increase the risk of cardiovascular disease. High blood glucose and elevated blood pressure can lead to vascular endothelial damage, subsequently leading to the formation of atherosclerosis.<sup>4-5</sup> The fundamental concept of atherosclerosis is arterial hardening due to the gradual accumulation of fatty plaques within the vessel walls. This plaque accumulation restricts blood flow.<sup>4</sup>

Atherosclerosis begins with endothelial activation, followed by a cascade of events (lipid accumulation, fibrous proliferation).<sup>5</sup> Non-enzymatic glycation reactions Interactions between glucose and proteins or lipoproteins within arterial walls are key mechanisms driving accelerated atherosclerosis under hyperglycemic conditions in type 2 diabetes mellitus. Prolonged hyperglycemia plays a central role in atherosclerosis pathogenesis by inducing multiple cellular alterations in vascular tissue that promote atherogenesis.<sup>17-18</sup>

17  
Another important biochemical process accompanying type 2 diabetes mellitus is the formation of Advanced Glycation End Products (AGEs). These AGEs likely also underlie the general inflammatory process.<sup>19</sup> The formation and accumulation of AGEs are associated with aging processes and are accelerated in diabetes.<sup>20</sup> AGEs are produced under hyperglycemic conditions, but their production also occurs in situations characterized by oxidative stress and inflammation.<sup>18</sup>

8 Activation of AGE receptors can induce cascading inflammatory responses that cause increased inflammation, oxidative stress, enhanced calcium deposition, and increased vascular smooth muscle apoptosis. This contributes to the development of atherosclerosis.<sup>21</sup>

4 The synergistic reaction between hypertension and hyperglycemia causes atherosclerosis formation through at least two mechanisms: elevated hemodynamic pressure in hypertensive conditions damages the endothelium and upregulates the renin-angiotensin-aldosterone system, oxidative stress, and inflammation, which contribute to the close relationship between diabetes and hypertension.<sup>22</sup>

1  
14  
2 High-sensitivity C-reactive protein (Hs-CRP) is a systemic inflammatory marker that emerges as an independent risk factor for cardiovascular disease.<sup>23-24</sup> Elevated Hs-CRP levels are associated with increased risk of thrombotic events, including myocardial infarction. Increased Hs-CRP levels are also associated with increased risk of developing diabetes later in life. Furthermore, it has been found that Hs-CRP levels are higher in diabetic patients compared to those without diabetes.<sup>25-27</sup> This study demonstrated that Hs-CRP and HbA1c showed a significant relationship between them. This is consistent with studies conducted by Seo HY, Khairinisa G, and Reddy KSS, which stated that HbA1c levels increased significantly with increasing Hs-CRP.<sup>6,7</sup> In contrast to the study conducted by Sari EP (2023), which stated that her study results showed no significant correlation between HbA1c levels and CRP (p-value=0.171 and r=0.218).<sup>8</sup> The key differences between this study and Sari EP (2023) involve measurement sensitivity and sample size. Sari used a semi-quantitative latex agglutination method for CRP with a detection threshold of 0.6 mg/dL (6 mg/L), which is less sensitive for detecting low-grade inflammation compared to our validated turbidimetric immunoassay capable of measuring Hs-CRP below 0.1 mg/L. Hs-CRP's superior sensitivity allows identification of subtle inflammatory changes specifically relevant to cardiovascular risk assessment. The sample size difference is also crucial; Sari's 24 subjects versus our 53 participants significantly affects statistical power to detect associations.<sup>8</sup>

Hs-CRP directly participates in the pathogenesis of atherosclerosis through the inflammation of endothelial cells and coronary arterial smooth muscle cells. Hs-CRP levels in various morbidity and mortality assessments are considered as one of the factors taken into account and as one of the predictor factors added to the Framingham score that enhances cardiovascular risk prediction. While this study identified a statistically significant correlation between HbA1c and Hs-CRP, potential confounding factors must be acknowledged. Variables such as BMI, lipid profile, and medications—particularly statins, anti-inflammatory agents, and metformin—are known to influence systemic inflammation. Previous studies demonstrate that metformin reduces Hs-CRP levels by suppressing proinflammatory cytokine secretion in hepatocytes and macrophages, indicating anti-inflammatory properties beyond glucose control.<sup>28</sup> However, due to data limitations, these variables were not adjusted for in the current analysis. Future studies incorporating multivariable regression models are warranted to control for confounding variables and clarify the independent relationship between glycemic control and systemic inflammation.

## CONCLUSIONS

1 This study demonstrates a significant positive correlation between HbA1c and Hs-CRP levels in T2DM, indicating that poor glycemic control is associated with increased systemic inflammation.

22 Additionally, Hs-CRP showed a significant correlation with systolic blood pressure but not with diastolic blood pressure, suggesting that inflammatory markers preferentially affect arterial stiffness and larger vessel dynamics. These findings support the use of Hs-CRP as a valuable biomarker for cardiovascular risk assessment in diabetic patients, particularly when combined with glycemic control parameters.

## ACKNOWLEDGEMENT

1  
23 The authors would like to express their sincere gratitude to all research team members who contributed to the successful completion of this study. We also acknowledge the support provided by the participants and the medical staff who facilitated data collection.

## AUTHORS CONTRIBUTION

2 The concept, analysis, and interpretation of data, drafting manuscript: Putri MA. Collecting data, assisted in developing research methodology: MAP, PA, DA, YI. Critical review of the manuscript: PA, DA, YI.

## FUNDING

16 This research was supported by an internal grant from Trisakti University.

## CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose

## REFERENCES

1. Gudisa B, Gemechis B. The incidence and predictors of poor glycemic control among adults with type 2 diabetes mellitus in ambulatory clinic of Mettu Karl Referral Hospital, South Western, Ethiopia: a prospective cross sectional study. *Int Arch Endocrinol Clin Res.* 2021;7(1). DOI:10.23937/2572-407X.1510024.
2. Rosengren A, Dikaiou P. Cardiovascular outcomes in type 1 and type 2 diabetes. *Diabetologia.* 2023;66:425–37. DOI:10.1007/s00125-022-05857-5.
3. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract.* 2022;183:109-19. DOI: 10.1016/j.diabres.2021.109119.
4. Verma S, Leiter LA. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. *Can J Cardiol.* 2018;34(5):575–84. DOI:10.1016/j.cjca.2017.12.005.
5. Rodriguez-Araujo G, Nakagami H. Pathophysiology of cardiovascular disease in diabetes mellitus. *Cardiovasc Endocrinol Metab.* 2018;7(1):4–9. DOI:10.1097/XCE.000000000000141.
6. Reddy KSS, Varadaraj P, Nallusamy G, et al. Correlation between hemoglobin A1c (HbA1c) and high-sensitivity C-reactive protein (Hs-CRP) in myocardial infarction patients and their six-month mortality follow-up. *Cureus.* 2024;16(8):e67070. DOI:10.7759/cureus.67070.

7. Seo YH, Shin HY. Relationship between Hs-CRP and HbA1c in diabetes mellitus patients: 2015–2017 Korean National Health and Nutrition Examination Survey. *Chonnam Med J.* 2021;57(1):62–8. DOI:10.4068/cmj.2021.57.1.62.
8. Sari EP, Sayekti S. Korelasi kadar HbA1c dengan C-reactive protein pasien diabetes melitus tipe 2. *Jurnal Sintesis Penelitian Sains Terapan dan Analisisnya.* 2023;4(1):1–7. DOI:10.56399/jst.v4i1.102.
9. Venkatamani Y, Raj JR, Ahmed MI, et al. Study of C-reactive protein, D-dimer in correlation with HbA1c levels in patients with diabetes mellitus type 2. *Panacea J Med Sci.* 2023;13(1):72–7. DOI:10.18231/j.pjms.2023.016.
10. Wolska A, Remaley AT. CRP and High-Sensitivity CRP: "What's in a Name?". *J Appl Lab Med.* 2022;7(6):1255–1258. DOI: <https://doi.org/10.1093/jalm/jfac076>
11. Johns I, Moschonas KE, Medina J, et al. Risk classification in primary prevention of CVD according to QRISK2 and JBS3 'heart age', and prevalence of elevated high-sensitivity C-reactive protein in the UK cohort of the EURIKA study. *Open Heart.* 2018;5:e000849. DOI:10.1136/openhrt-2018-000849
12. Wang B, Yang Y, Li X. Interaction of hypertension and insulin resistance exacerbates the occurrence of diabetes mellitus in healthy individuals. *J Diabetes Res.* 2022;2022:1–8. DOI:10.1155/2022/1234567.
13. Midha T. Correlation between hypertension and hyperglycemia among young adults in India. *World J Clin Cases.* 2015;3(2):171–6. DOI:10.12998/wjcc.v3.i2.171.
14. Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, et al. Hypertension and diabetes mellitus coprediction and time trajectories. *Hypertension.* 2018;71(3):422–8. DOI:10.1161/HYPERTENSIONAHA.117.10546.
15. Kim HL. Arterial stiffness and hypertension. *Clin Hypertens.* 2023;29(1):31. DOI:10.1186/s40885-023-00258-1.
16. Kandil H, Soliman A, Alghamdi NS, et al. Using mean arterial pressure in hypertension diagnosis versus using either systolic or diastolic blood pressure measurements. *Biomedicines.* 2023;11(3):849. DOI:10.3390/biomedicines11030849.
17. Geraghty L, Wood MJ. Cardiovascular disease in women: from pathophysiology to novel and emerging risk factors. *Heart Lung Circ.* 2021;30(1):9–17. DOI:10.1016/j.hlc.2020.05.108.
18. Schmidt AM. Diabetes mellitus and cardiovascular disease. *Arterioscler Thromb Vasc Biol.* 2019;39(4):558–66. DOI:10.1161/ATVBAHA.119.310961.
19. Lee J, Yun JS, Ko SH. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. *Nutrients.* 2022;14(15):3086. DOI:10.3390/nu14153086.
20. Mao L, Yin R, Yang L, et al. Role of advanced glycation end products on vascular smooth muscle cells under diabetic atherosclerosis. *Front Endocrinol (Lausanne).* 2022;13:983723. DOI:10.3389/fendo.2022.983723.
21. Putri MA, Amani P, Adriani D, et al. Importance of exercise in mitigating age-related cardiac apoptosis. *Sriwijaya Journal of Medicine.* 2023;6(3):94–101. DOI:10.32539/sjm.v6i3.208.
22. Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. *Circ Res.* 2020;126(11):1501–25. DOI:10.1161/CIRCRESAHA.120.315913.

23. Dayoub A, Khayat MI, Zrieki A. Association of high sensitivity C-reactive protein (Hs-CRP) with poor glycaemic control and coronary heart disease in type 2 diabetes mellitus. *Res J Pharm Technol.* 2023;16(1):193–9. DOI:10.52711/0974-360X.2023.00036.
24. Sasidharan A, Krishnamurthy A, Tagore S, et al. C-reactive protein and glycemic control in adults with type 2 diabetes mellitus. *J Med Radiol Pathol Surg.* 2016;2(1):1–4. DOI:10.15713/ins.jmrps.56.
25. He P, Fan SY, Guan JQ, et al. Mediation analysis for the relationship between dyslipidemia and coronary artery disease via hypersensitive C-reactive protein in a case-control study. *Coron Artery Dis.* 2020;31(7):613–9. DOI:10.1097/MCA.0000000000000911.
26. Patil V, Avhad A, Kulkarni A, et al. High-sensitive C-reactive protein in patients with coronary artery disease. *J Nat Sci Biol Med.* 2020;11(1):39–44. DOI:10.4103/jnsbm.JNSBM\_159\_19.
27. Indrajaya T, Saleh MI, Miliyandra M. The role of high-sensitivity C-reactive protein serum in assessing troponin T in acute myocardial infarction. *Open Access Maced J Med Sci.* 2020;8(B):1053–6. DOI:10.3889/oamjms.2020.5495.
28. Karbalaee-Hasani A, Khadive T, Eskandari M, et al. Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Ann Pharmacother.* 2021;55(9):1096–109. DOI:10.1177/1060028020985303.

**Table 1.** Distribution of Subject Characteristics

Variable	Frequency	min	max	mean±SD
<b>Gender</b>				
Men	17 (32.1%)			
Women	36 (67.9%)			
<b>Age (year)</b>				
40 – 60	40 (75.5%)			
>60	13 (24.5%)			
<b>Inflammation risk categories</b>				
Low risk (< 1.0 mg/L)	8 (15.1%)			
Intermediate risk ( 1.0 – 3.0 mg/L)	28 (52.8%)			
High risk (>3.0 mg/L)	17 (32.1 %)			
<b>Tekanan Darah</b>				
Sistolik (mmHg)		100	202	138.2 ± 19.6
Diastolik (mmHg)		70	115	87.7 ± 9.2
<b>Serum Level</b>				
HbA1c (%)		4.8	11.3	7.2 ± 1.8
Hs-CRP (mg/L)		0.3	9.7	2.9 ± 2.4

Table 2. Correlation Analysis Between HbA1C, Blood Pressure and Hs-CRP

		Hs-CRP
<b>HbA1C</b>	spearman	.336**
	Correlation	
	Sig.(2-tailed)	.014*
<b>Systolic blood pressure</b>	spearman	.277**
	Correlation	
	Sig.(2-tailed)	.044*
<b>Diastolic blood pressure</b>	spearman	.059
	Correlation	
	Sig.(2-tailed)	.673

Spearman

\*Correlation is significant at the 0.05 level (2-tailed)

\*\*Correlation is significant at the 0.01 level (2-tailed)

## [JBK] Submission Acknowledgement

---

Dr. dr. Husnun Amalia, Sp.M <jbiomedkes@trisakti.ac.id>

Mon, Jul 14, 2025 at 12:49  
AM

To: mustika anggiane putri <inge.mustika@trisakti.ac.id>

mustika anggiane putri:

Thank you for submitting the manuscript, "Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and hs-CRP Levels in Type 2 Diabetes Mellitus " to Jurnal Biomedika dan Kesehatan. With the online journal management system that we are using, you will be able to track its progress through the editorial process by logging in to the journal web site:

Submission URL: <https://jbiomedkes.org/index.php/jbk/authorDashboard/submission/725>

Username: mustika

If you have any questions, please contact me. Thank you for considering this journal as a venue for your work.

Dr. dr. Husnun Amalia, Sp.M

---

[Jurnal Biomedika dan Kesehatan](#)

[Jl. Kyai Tapa No. 260 Kampus B, Grogol, DKI Jakarta 11440](#)

Telp. (021) 5672731 | E-mail: [jbiomedkes@trisakti.ac.id](mailto:jbiomedkes@trisakti.ac.id)

99+

Compose

Mail

1

Inbox 2,586

Chat

Starred

Snoozed

Meet

Sent

Drafts 42

Categories

Purchases 11

More

Labels

[JBK] New notification from Jurnal Biomedika dan Kesehatan Inbox x



**Husnun Amalia** <husnun\_a@trisakti.ac.id>  
to me

You have a new notification from Jurnal Biomedika dan Kesehatan:

You have been added to a discussion titled "Turnitin document" regarding the submission "Glyce

Link: <https://jbiomedkes.org/index.php/jbk/authorDashboard/submission/725>

Dr. dr. Husnun Amalia, Sp.M

---

[Jurnal Biomedika dan Kesehatan](#)

Jl. Kyai Tapa No. 260 Kampus B, Grogol, DKI Jakarta 11440

Telp. (021) 5672731 | E-mail: [jbiomedkes@trisakti.ac.id](mailto:jbiomedkes@trisakti.ac.id)

Reply

Forward



99+

Compose

Mail

1

Inbox 2,586

Chat

Starred

Snoozed

Meet

Sent

Drafts 42

Categories

Purchases 11

More

Labels

Revisi Artikel Inbox ×



**Jurnal Biomedika dan Kesehatan** <jbiomedkes@trisakti.ac.id> to me

Dear Author

Berikut kami kirimkan file hasil review oleh reviewer dan editor. Mohon untuk segera di revisi dan akhir July 2025. Selain itu dimohon untuk melakukan pembayaran APC sebesar Rp.2.750.000 se

Terima Kasih

Salam  
Eka Nurmayanti

--

**Jurnal Biomedika dan Kesehatan**

Faculty of Medicine, Trisakti University  
Jalan Kyai Tapa No. 260 (Kampus B), Grogol 11440  
Gedung Ki Hadjar Dewantara Lantai 1  
Tlp. 021-565 5578 Ext. 2502



**UNIVERSITAS TRISAKTI**  
*"Is a one stop learning for sustainable development"*  
Kampus A, Jl. Kyai Tapa No.1, Grogol  
Jakarta Barat 11440 - INDONESIA  
[www.trisakti.ac.id](http://www.trisakti.ac.id)  
(t) +62-21.566 3232, (f) +62-21.567 3001

2 Attachments • Scanned by Gmail Add all to Drive



Reply Forward Share in chat <sup>New</sup>

99+

Compose

Mail

1

Inbox 2,586

Chat

Starred

Snoozed

Meet

Sent

Drafts 42

Categories

Purchases 11

More

Labels

[JBK] Editor Decision Inbox ×



**Husnun Amalia** <husnun\_a@trisakti.ac.id>  
to me, Amani, Adriani, Imran

mustika anggiane putri, Amani P, Adriani D, Imran Y:

We have reached a decision regarding your submission to Jurnal Biomedika dan Kesehatan, "GI

Our decision is: Revisions Required

There are suggestions for improving the manuscript from the reviewer, according to the files we f

Article Processing Charge :

Please to pay an Article Processing Charge (APC) in order for your article to be published in our

The following is a link to make a payment :

<https://forms.gle/9iUSzNs25Dt4zMmG9>

Best regards,  
Husnun Amalia

---

[Jurnal Biomedika dan Kesehatan](#)

Jl. Kyai Tapa No. 260 Kampus B, Grogol, DKI Jakarta 11440

Telp. (021) 5672731 | E-mail: [jbiomedkes@trisakti.ac.id](mailto:jbiomedkes@trisakti.ac.id)

---

2 Attachments • Scanned by Gmail Add all to Drive



Reply Reply all Forward 😊

Workflow

Publication

Submission

Review

Copyediting

Production

Round 1

## Round 1 Status

Submission accepted.

Jurnal Biomedika dan Kesehatan

[← Back to Submissions](#)[UBKJ EDITOR DECISION](#)

2025-07-14 11:58 AM

## Reviewer's Attachments

Q Search

	4275	<a href="#">Artikel OA 725 for revision.docx</a>	July 14, 2025
	4276	<a href="#">checklis Artikel 725.docx</a>	July 14, 2025

## Revisions

Q Search

Upload File

▶		4313	<a href="#">artikel-oa-725-for-revision.docx</a>	July 18, 2025	Article Text
---	--	------	--------------------------------------------------	---------------------	--------------



4314

Plagiarism\_statements.doc

July  
18,  
2025

Other

### Review Discussions

[Add discussion](#)

Name

From

Last  
Reply

Replies

Closed

*No Items*

[← Back to Submissions](#)

Submission

Review

Copyediting

Production

## Submission Files

[Q Search](#)

- ▶ 📄 4265 [mustika\\_hba1c\\_hscrp\\_manuskrip\\_JBK\\_2025.docx](#)

July 14, 2025    Article Text
- ▶ 📄 4267 [Artikel OA 725 for review.docx](#)

July 14, 2025    Article Text

[Download All Files](#)

## Pre-Review Discussions


[Add discussion](#)

Name	From	Last Reply	Replies	Closed
▶ <a href="#">Comments for the Editor</a>	mustika 2025-07-14 12:44 AM	-	0	<input type="checkbox"/>
<a href="#">Turnitin document</a>	husnun_a 2025-07-14 12:01 PM	-	0	<input type="checkbox"/>

**Participants**

Husnun Amalia (husnun\_a)

mustika anggiane putri (mustika)

Messages	
Note	From
Dear author we sent the turnitin document	husnun_a 2025-07-14 12:01 PM
 <a href="#">Glycemic Control and Cardiovascular Risk Assessment_ A Study on HbA1c and hs-CRP Levels in Type 2 Diabetes Mellitus.pdf</a>	

**Add Message**

Participants [Edit](#)

mustika anggiane putri (mustika)

Messages	
Note	From
<p>Dear Editor,</p> <p>We are pleased to submit our research manuscript titled "Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and hs-CRP Levels in Type 2 Diabetes Mellitus" for consideration in your esteemed journal.</p> <p>This study addresses a crucial health concern in Indonesia, where diabetes rates are rising rapidly. Our research examines how blood sugar control relates to inflammation markers in diabetic patients, which could help predict heart disease risk. Using data from 59 patients in East Jakarta, we found a significant connection between long-term blood sugar levels (HbA1c) and inflammation markers (hs-CRP). These findings could help doctors better identify diabetic patients at higher risk for heart problems, enabling earlier intervention and potentially saving lives in our community.</p> <p>Thank you for your consideration.</p> <p>Sincerely, Mustika Anggiane Putri</p>	<p>mustika 2025-07-14 12:44 AM</p>

[Add Message](#)



## ORIGINAL ARTICLE

### Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and hs-CRP Levels in Type 2 Diabetes Mellitus

Kontrol Glikemik dan Penilaian Risiko Kardiovaskular: Studi tentang Kadar HbA1c dan hs-CRP pada Diabetes Melitus Tipe 2

Mustika Anggiane Putri<sup>1</sup>, Patwa Amani<sup>1</sup>, Donna Adriani<sup>1</sup>, Yudhisman Imran<sup>2</sup>

<sup>1</sup> Departement of Physiology, Faculty of medicine, Universitas Trisakti, Jakarta, Indonesia

<sup>2</sup> Department of Neurology, Faculty of medicine, Universitas Trisakti, Jakarta, Indonesia

[inge.mustika@trisakti.ac.id](mailto:inge.mustika@trisakti.ac.id) (Correspondence email)

<https://doi.org/10.56186/jkbb.xxx>

#### ABSTRACT

##### Background:

Diabetes mellitus represents a major risk factor for cardiovascular disease. Diabetic patients have a 2-4 fold higher risk of developing coronary heart disease compared to non-diabetic populations. Cardiovascular complications are the primary cause of morbidity and mortality in diabetic patients, with cardiovascular-related deaths accounting for 65-75% of total deaths in the diabetic population. Poor glycemic control is a key factor in the pathogenesis of cardiovascular complications in diabetes. Chronic hyperglycemia triggers various pathophysiological mechanisms, including increased oxidative stress, systemic inflammation, endothelial dysfunction, and accelerated atherosclerosis. Hemoglobin A1C (HbA1C) as a long-term glycemic control parameter has been proven to strongly correlate with microvascular and macrovascular complications in diabetes. This study aims to analyze the relationship between glycemic control assessed through HbA1C and systemic inflammatory status measured through hs-CRP in type 2 diabetes mellitus patients.

**Methods:** This study employed an analytical cross-sectional design with 59 type 2 diabetes mellitus subjects. The ELISA technique was used to assess HbA1c levels as glycemic control parameters, hs-CRP as inflammatory predictors, and NT-ProBNP as heart failure risk markers.

**Results:** 55.9% of subjects showed poor glycemic control (HbA1C  $\geq$  6.5%). Based on hs-CRP levels, 28.8% showed high inflammatory risk, 10.2% experienced acute inflammation, and 47.5% showed average risk. Statistical analysis revealed a significant correlation between HbA1C and hs-CRP (p-value = 0.026) with a Pearson correlation coefficient of 0.290.

**Conclusion:** A significant relationship exists between HbA1C and hs-CRP as inflammatory markers.

**Keywords:** Cardiovascular risk; type 2 diabetes mellitus; HbA1C; hs-CRP; inflammation

#### ABSTRAK

**Latar Belakang:**

Diabetes melitus merupakan faktor risiko utama penyakit kardiovaskular. Pasien diabetes memiliki risiko 2-4 kali lebih tinggi mengalami penyakit jantung koroner dibandingkan populasi non-diabetes. Komplikasi kardiovaskular menjadi penyebab utama morbiditas dan mortalitas pada pasien diabetes, dengan angka kematian akibat penyakit kardiovaskular mencapai 65-75% dari total kematian populasi diabetes. Kontrol glikemik yang buruk menjadi faktor kunci patogenesis komplikasi kardiovaskular pada diabetes. Hiperglikemia kronis memicu berbagai mekanisme patofisiologis, termasuk peningkatan stres oksidatif, inflamasi sistemik, disfungsi endotel, dan percepatan proses aterosklerosis. Hemoglobin A1C (HbA1C) sebagai parameter kontrol glikemik jangka panjang telah terbukti berkorelasi kuat dengan risiko komplikasi mikrovaskular dan makrovaskular pada diabetes. Penelitian ini bertujuan menganalisis hubungan antara kontrol glikemik yang dinilai melalui HbA1C dengan status inflamasi sistemik yang diukur melalui hs-CRP pada pasien diabetes melitus tipe 2.

**Metode:** Penelitian ini menggunakan desain analitik potong lintang dengan 59 responden diabetes melitus tipe 2. Teknik ELISA digunakan untuk menilai kadar HbA1c sebagai parameter kontrol glikemik, hs-CRP sebagai prediktor inflamasi, dan NT-ProBNP sebagai penanda risiko gagal jantung.

**Hasil:** 55,9% responden menunjukkan kontrol glikemik buruk (HbA1C  $\geq$  6,5%). Berdasarkan kadar hs-CRP, 28,8% menunjukkan risiko inflamasi tinggi, 10,2% mengalami inflamasi akut, dan 47,5% menunjukkan risiko rata-rata. Analisis statistik menunjukkan korelasi signifikan antara HbA1C dan hs-CRP ( $p$ -value = 0,026) dengan koefisien korelasi Pearson 0,290.

**Kesimpulan:** Terdapat hubungan signifikan antara HbA1C dan hs-CRP sebagai penanda inflamasi.

**Kata kunci:** Diabetes melitus tipe 2; HbA1C; hsCR; inflamasi

## INTRODUCTION

The global prevalence of type 2 diabetes mellitus (T2DM) has demonstrated a significant escalation attributable to alterations in human lifestyle patterns and behavioral modifications.<sup>(1,2)</sup> Diabetes has emerged as a predominant cardiometabolic disorder, affecting 10.5% of the adult population (aged 20-79 years) in 2021, with projections indicating an increase to 12.2% by 2045.<sup>(2,3)</sup> The prevalence exhibits higher rates in urban areas (12.1%) compared to rural regions (8.3%), and in high-income countries (11.1%) versus low-income nations (5.5%). The most substantial relative increase is projected to occur in middle-income countries (21.1%) compared to high-income (12.2%) and low-income countries (11.9%). In Indonesia, T2DM prevalence demonstrates an alarming trend, with continuously rising incidence rates paralleling societal changes in lifestyle and dietary patterns.<sup>(1)</sup>

Diabetes mellitus extends beyond an isolated health concern, constituting a principal risk factor for cardiovascular disease. Diabetic patients exhibit a 2-4 fold elevated risk of developing coronary heart disease compared to non-diabetic populations.<sup>(4)</sup> Cardiovascular complications represent the primary cause of morbidity and mortality in diabetic patients, with cardiovascular-related deaths accounting for 65-75% of total mortality in the diabetic population.<sup>(4,5)</sup> Poor glycemic control serves as a pivotal factor in the pathogenesis of cardiovascular complications in diabetes. Chronic hyperglycemia triggers various pathophysiological mechanisms, including enhanced oxidative stress, systemic inflammation, endothelial dysfunction, and accelerated atherosclerosis.<sup>(1)</sup> This condition creates a vicious cycle that accelerates the progression of cardiovascular disease in diabetic patients.<sup>(1,2)</sup>

**Commented [MOU1]:** Penulisan sumber rujukan superskript tanpa tanda kurung  
Contoh :  
...lifestyle patterns and behavioral modifications.<sup>1,2</sup>

Hemoglobin A1C (HbA1C), as a long-term glycemic control parameter, has been demonstrated to strongly correlate with microvascular and macrovascular complications in diabetes.(6) HbA1C reflects the average blood glucose levels over the preceding 8-12 weeks and serves as the gold standard for monitoring glycemic control in diabetic patients. Conversely, high-sensitivity C-Reactive Protein (hs-CRP) represents a sensitive systemic inflammatory biomarker that has been recognized as an independent predictor of cardiovascular risk. Low-grade chronic inflammation constitutes a crucial characteristic of type 2 diabetes mellitus and plays a significant role in the development of cardiovascular complications.(7) Elevated hs-CRP levels in diabetic patients not only reflect systemic inflammatory status but also correlate with glycemic control levels and future cardiovascular event risk.(8,9) Given the concerning projected increase in diabetes prevalence, particularly in middle-income countries such as Indonesia, the identification of predictive biomarkers for cardiovascular risk becomes critically important for timely preventive interventions. Therefore, understanding the relationship between glycemic control and inflammatory status becomes essential in the comprehensive management of diabetic patients.

This study aims to analyze the relationship between glycemic control assessed through HbA1C and systemic inflammatory status measured through hs-CRP in type 2 diabetes mellitus patients. Although the relationship between glycemic control and cardiovascular complications in type 2 diabetes mellitus has been extensively documented, research specifically analyzing the correlation between HbA1C and hs-CRP as systemic inflammatory biomarkers in the Indonesian population remains limited. This study contributes novel insights into understanding the interaction between long-term glycemic control and chronic inflammatory status in T2DM patients in Indonesia, who possess distinct demographic and genetic characteristics compared to Western populations.

## **METHODS**

This analytical cross-sectional study was conducted among the Prolanis Diabetes Clinic population in East Jakarta. A total of 59 subjects were selected using purposive sampling through questionnaire interviews, meeting inclusion criteria of male and female participants aged 40-60 years with type 2 diabetes mellitus. Exclusion criteria comprised individuals with comorbidities such as cardiovascular, neurological, malignancy, and pulmonary diseases, as well as those with current illness or history of conditions that could elevate hs-CRP levels including severe infections, non-infectious inflammatory diseases such as gout arthritis, rheumatoid arthritis, and cancer. Blood plasma samples were collected for HbA1c examination as glycemic control parameters and hs-CRP as cardiovascular risk markers, conducted professionally in collaboration with PRODIA Laboratory using ELISA technique. The research protocol was approved by the Ethics Committee of Trisakti University Faculty of Medicine (No. 055/KER/FK/II/2023). Univariate analysis was performed to present descriptive data including age, gender, blood pressure, HbA1c and hs-CRP levels, with numerical data presented as mean and standard deviation while nominal data were expressed as percentages. Data processing was conducted using SPSS statistical software with Pearson correlation analysis to assess the relationship between HbA1c and hs-CRP levels.

## RESULTS

The distribution of subject characteristics based on gender, age, blood pressure, HbA1C levels, and hs-CRP is presented in Table 1. This study involved 59 subjects with type 2 diabetes mellitus, comprising 41 females (69.5%) and 18 males (30.5%). The age distribution revealed that the majority of subjects were within the 40-60 years age range, accounting for 46 individuals (77.9%), while 13 subjects (22.0%) were aged >60 years.

**Table 1.** Distribution of Subject Characteristics

Variable	Frequency	min	max	mean±SD
<b>Gender</b>				
Men	18 (30,5%)			
Women	41 (69,5%)			
<b>Age (year)</b>				
40 – 60	46 (77,9%)			
>60	13 (22,0%)			
<b>Glycemic control status</b>				
Good glycemic control (< 6,5%)	26 (44,1%)			
Poor glycemic control (≥6,5%)	33 (55,9%)			
<b>Inflammation risk categories</b>				
Low risk (< 10 mg/L)	8 (13,6%)			
Average risk ( 1,0 – 3,0 mg/L)	28 (47,5%)			
High risk (>3,0 mg/L)	17 (28,8%)			
Acute inflammation (> 10 mg/L)	6 (10,2%)			
<b>Tekanan Darah</b>				
Sistolik (mmHg)		100	202	138,9 ± 18,9
Diastolik (mmHg)		70	115	87,9 ± 9,0
<b>Serum Level</b>				
HbA1c (%)		4.8	11.3	7.3 ± 1.9
hs-CRP (mg/L)		0.3	28.0	4.3 ± 5,1

**Commented [MOU2]:** Mohon perbaiki, penulisan desimal menggunakan titik  
Contoh : 69.5

The mean systolic and diastolic blood pressure values in this study demonstrated a mean systolic blood pressure of 138.9 mmHg and diastolic blood pressure of 87.9 mmHg. The mean HbA1C level among subjects was 7.3%. Twenty-six subjects (44.1%) were classified as having normal glycemic control (HbA1C <6.5%), while 33 subjects (55.9%) were categorized as having diabetes (≥6.5%), indicating poor glycemic control. The study results showed a mean hs-CRP level of 4.3 mg/dL. Based on the inflammatory risk classification according to hs-CRP levels, 17 subjects (28.8%) exhibited high inflammatory risk (>3.0 mg/L) and 6 subjects (10.2%) experienced acute inflammation (>10 mg/L). Nearly half of the participants, 28 subjects (47.5%), demonstrated average inflammatory risk (1.0-3.0 mg/L), while 8 subjects (13.6%) had low risk (<1.0 mg/L).

A non-parametric Spearman correlation analysis was conducted to examine the relationships between glycemic control parameters, hemodynamic variables, and hs-CRP as a cardiovascular risk

predictor among 59 patients with type 2 diabetes mellitus. The results of the correlation analysis are presented in Table 2. The analysis revealed a statistically significant positive correlation between HbA1c levels and hs-CRP concentrations ( $r = 0.386$ ,  $p = 0.003$ ). This moderate correlation indicates that poorer glycemic control, as reflected by elevated HbA1c levels, is associated with increased hs-CRP levels, suggesting a relationship between chronic hyperglycemia and systemic inflammation in diabetic patients.

Regarding hemodynamic parameters, systolic blood pressure demonstrated a significant positive correlation with hs-CRP levels ( $r = 0.311$ ,  $p = 0.016$ ). This finding suggests that elevated systolic blood pressure is associated with increased inflammatory markers, potentially indicating the role of hypertension in cardiovascular risk enhancement through inflammatory pathways. Conversely, diastolic blood pressure showed no significant correlation with hs-CRP levels ( $r = 0.092$ ,  $p = 0.487$ ).

## DISCUSSIONS

Based on the research data presented in Table 2, there is a distinct pattern of relationship between hs-CRP and the components of systolic and diastolic blood pressure. The Spearman correlation analysis revealed a significant relationship between hs-CRP and systolic blood pressure ( $r=0.311$ ;  $p=0.016$ ), however, no significant relationship was found with diastolic blood pressure ( $r=0.092$ ;  $p=0.487$ ). This finding provides an interesting insight into how systemic inflammatory markers interact with cardiovascular hemodynamic parameters in patients with type 2 diabetes mellitus.(8,9) Previous studies have established the relationship between diabetes and the occurrence of hypertension.(10) Diabetes can increase the risk of hypertension and vice versa, and the simultaneous presence of diabetes and hypertension can increase the risk of more serious disease complications such as cardiovascular disease.(10-12)

Hs-CRP is an inflammatory marker produced by the liver and elevated during inflammation, including in the process of atherosclerosis, and has been proven as a marker that can predict cardiovascular disease risk.(6) This study demonstrated a significant relationship between systolic blood pressure and hs-CRP but not with diastolic blood pressure. This phenomenon can occur because systolic blood pressure is more sensitive to vascular inflammatory changes compared to diastolic pressure, as systolic pressure reflects the strength of cardiac contraction and the elasticity of larger arterial blood vessels.(13) When chronic inflammation occurs, as indicated by increased hs-CRP, arterial walls become stiffer and less elastic, which directly affects systolic pressure.(13) Conversely, diastolic pressure more reflects the resistance of smaller peripheral blood vessels and is not significantly influenced by inflammatory processes occurring in larger blood vessels.(14) Poor glycemic conditions trigger systemic inflammation that increases hs-CRP.(1,2,6) This inflammation contributes to arterial stiffening, which has a greater impact on the systolic component of blood pressure.(13) Therefore, hs-CRP as a predictor of cardiovascular inflammation demonstrates a stronger correlation with systolic pressure because both reflect vascular damage occurring in major arterial blood vessels, while diastolic pressure remains more stable and is not significantly affected by systemic inflammatory changes measured through hs-CRP.(13,14)

High blood pressure (hypertension) and diabetes frequently occur simultaneously and increase the risk of cardiovascular disease. Elevated blood glucose levels and high blood pressure

can damage vascular endothelium, subsequently leading to the formation of atherosclerosis.(4,5) The fundamental concept of atherosclerosis is arterial hardening due to the gradual accumulation of fatty plaques within the vessel walls. This plaque accumulation restricts blood flow.(4)

Atherosclerosis begins with endothelial activation, followed by a cascade of events (lipid accumulation, fibrous proliferation). (5) Non-enzymatic glycation reactions between glucose and proteins or lipoproteins in arterial walls represent one of the important mechanisms responsible for accelerated atherosclerosis formation under hyperglycemic conditions in type 2 diabetes mellitus. (15) Prolonged exposure to hyperglycemia is believed to be a primary factor in the pathogenesis of atherosclerosis in diabetes. Hyperglycemia induces numerous changes at the cellular level of vascular tissue that potentially accelerate the atherosclerotic process. (16)

Another important biochemical process accompanying type 2 diabetes mellitus is the formation of Advanced Glycation End Products (AGEs). These AGEs likely also underlie the general inflammatory process. (17) The formation and accumulation of AGEs are associated with aging processes and are accelerated in diabetes. (17) AGEs are produced under hyperglycemic conditions, but their production also occurs in situations characterized by oxidative stress and inflammation. (18) Activation of AGE receptors can induce cascading inflammatory responses that cause increased inflammation, oxidative stress, enhanced calcium deposition, and increased vascular smooth muscle apoptosis. This contributes to the development of atherosclerosis.(19)

The synergistic reaction between hypertension and hyperglycemia causes atherosclerosis formation through at least two mechanisms: elevated hemodynamic pressure in hypertensive conditions damages the endothelium and upregulates the renin-angiotensin-aldosterone system, oxidative stress, and inflammation, which contribute to the close relationship between diabetes and hypertension.(20)

High-sensitivity C-reactive protein (hs-CRP) is a systemic inflammatory marker that emerges as an independent risk factor for cardiovascular disease. Elevated hs-CRP levels are associated with increased risk of thrombotic events, including myocardial infarction. Increased hs-CRP levels are also associated with increased risk of developing diabetes later in life. Furthermore, it has been found that hs-CRP levels are higher in diabetic patients compared to those without diabetes. (21,22) This study demonstrated that hs-CRP and HbA1c showed a significant relationship between them. This is consistent with studies conducted by Yoo Han Seo, Khairinisa G, and Reddy KSS, which stated that HbA1c levels increased significantly with increasing hs-CRP.(6,7) In contrast to the study conducted by Evi Puspita Sari (2023), which stated that her study results showed no significant correlation between HbA1c levels and CRP (p-value=0.171 and r=0.218). (8)

Hs-CRP directly participates in the pathogenesis of atherosclerosis through the inflammation of endothelial cells and coronary arterial smooth muscle cells. hs-CRP levels in various morbidity and mortality assessments are considered as one of the factors taken into account and as one of the predictor factors added to the Framingham score that enhances cardiovascular risk prediction.

## CONCLUSIONS

This study demonstrates a significant positive correlation between HbA1c and hs-CRP levels in type 2 diabetes mellitus patients, indicating that poor glycemic control is associated with

increased systemic inflammation. Additionally, hs-CRP showed a significant correlation with systolic blood pressure but not with diastolic blood pressure, suggesting that inflammatory markers preferentially affect arterial stiffness and larger vessel dynamics. These findings support the use of hs-CRP as a valuable biomarker for cardiovascular risk assessment in diabetic patients, particularly when combined with glycemic control parameters.

## ACKNOWLEDGEMENT

The authors would like to express their sincere gratitude to all research team members who contributed to the successful completion of this study. We also acknowledge the support provided by the participants and the medical staff who facilitated data collection.

## AUTHORS CONTRIBUTION

The concept, analysis, and interpretation of data, drafting manuscript: Putri MA. Collecting data, assisted in developing research methodology: MAP, PA, DA, YI. Critical review of the manuscript: PA, DA, YI.

## FUNDING

This research was supported by an internal grant from Trisakti University.

## CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose

## REFERENCES

1. Gudisa B, Gemechis B. The incidence and predictors of poor glycemic control among adults with type 2 diabetes mellitus in ambulatory clinic of Mettu Karl Referral Hospital, South Western, Ethiopia: a prospective cross sectional study. *Int Arch Endocrinol Clin Res.* 2021;7(1). doi:10.23937/2572-407X.1510024.
2. Rosengren A, Dikaïou P. Cardiovascular outcomes in type 1 and type 2 diabetes. *Diabetologia.* 2023;66:425–437. doi:10.1007/s00125-022-05857-5.
3. Astutisari IDAEC, Darmini AAY, Wulandari IAP. Hubungan pola makan dan aktivitas fisik dengan kadar gula darah pada pasien diabetes melitus tipe 2 di Puskesmas Manggis I. *J Riset Kesehatan Nasional.* 2022;6(2):79–87. doi:10.37294/jrkn.v6i2.350.
4. Verma S, Leiter LA. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. *Can J Cardiol.* 2018;34(5):575–584. doi:10.1016/j.cjca.2017.12.005.
5. Rodriguez-Araujo G, Nakagami H. Pathophysiology of cardiovascular disease in diabetes mellitus. *Cardiovasc Endocrinol Metab.* 2018;7(1):4–9. doi:10.1097/XCE.000000000000141.
6. Reddy KSS, Varadaraj P, Nallusamy G, SenthilNathan S. Correlation between hemoglobin A1c (HbA1c) and high-sensitivity C-reactive protein (hs-CRP) in myocardial infarction patients and their six-month mortality follow-up. *Cureus.* 2024;16(8):e67070. doi:10.7759/cureus.67070.

### Commented [MOU3]: Perbaiki :

1. Penulisan nama author: setelah 3 author, dilanjutkan et al
2. Nama Jurnal, disingkat sesuai [https://www.issn.org/wp-content/uploads/2024/02/twa\\_current.pdf](https://www.issn.org/wp-content/uploads/2024/02/twa_current.pdf)
3. Penulisan halaman bila puluh atau ratus nya sama, maka tidak ditulis :
- Contoh 575-584 → 575-84
4. Penulisan doi dalam huruf besar : doi → DOI

7. Seo YH, Shin HY. Relationship between hs-CRP and HbA<sub>1c</sub> in diabetes mellitus patients: 2015–2017 Korean National Health and Nutrition Examination Survey. *Chonnam Med J.* 2021;57(1):62–68. doi:10.4068/cmj.2021.57.1.62.
8. Sari EP, Sayekti S. Korelasi kadar HbA<sub>1c</sub> dengan C-reactive protein pasien diabetes melitus tipe 2. *J Sintesis.* 2023;4(1):1–7. doi:10.56399/jst.v4i1.102.
9. Venkatamani Y, Raj JR, Ahmed MI, R HM, BR B. Study of C-reactive protein, D-dimer in correlation with HbA<sub>1c</sub> levels in patients with diabetes mellitus type 2. *Panacea J Med Sci.* 2023;13(1):72–77. doi:10.18231/j.pjms.2023.016.
10. Wang B, Yang Y, Li X. Interaction of hypertension and insulin resistance exacerbates the occurrence of diabetes mellitus in healthy individuals. *J Diabetes Res.* 2022;2022:1–8. doi:10.1155/2022/1234567.
11. Midha T. Correlation between hypertension and hyperglycemia among young adults in India. *World J Clin Cases.* 2015;3(2):171–176. doi:10.12998/wjcc.v3.i2.171.
12. Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, Ferrannini E. Hypertension and diabetes mellitus coprediction and time trajectories. *Hypertension.* 2018;71(3):422–428. doi:10.1161/HYPERTENSIONAHA.117.10546.
13. Kim HL. Arterial stiffness and hypertension. *Clin Hypertens.* 2023;29(1):31. doi:10.1186/s40885-023-00258-1.
14. Kandil H, Soliman A, Alghamdi NS, Jennings JR, El-Baz A. Using mean arterial pressure in hypertension diagnosis versus using either systolic or diastolic blood pressure measurements. *Biomedicines.* 2023;11(3):849. doi:10.3390/biomedicines11030849.
15. Geraghty L, Wood MJ. Cardiovascular disease in women: from pathophysiology to novel and emerging risk factors. *Heart Lung Circ.* 2021;30(1):9–17. doi:10.1016/j.hlc.2020.05.108.
16. Schmidt AM. Diabetes mellitus and cardiovascular disease. *Arterioscler Thromb Vasc Biol.* 2019;39(4):558–566. doi:10.1161/ATVBAHA.119.310961.
17. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. *Cardiovasc Res.* 2004;63(4):582–592. doi:10.1016/j.cardiores.2004.05.001.
18. Mao L, Yin R, Yang L, Zhao D. Role of advanced glycation end products on vascular smooth muscle cells under diabetic atherosclerosis. *Front Endocrinol (Lausanne).* 2022;13:983723. doi:10.3389/fendo.2022.983723.
19. Putri MA, Amani P, Adriani D, Khairani R. Importance of exercise in mitigating age-related cardiac apoptosis. *Sriwijaya J Med.* 2023;6(3):94–101. doi:10.32539/sjm.v6i3.208.
20. Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. *Circ Res.* 2020;126(11):1501–1525. doi:10.1161/CIRCRESAHA.120.315913.
21. King DE, Mainous AG, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. *Diabetes Care.* 2003;26(5):1535–1539. doi:10.2337/diacare.26.5.1535.
22. Sasidharan A, Krishnamurthy A, Tagore S, Nagaraj T, Santosh HN, Nigam H. C-reactive protein and glycemic control in adults with type 2 diabetes mellitus. *J Med Radiol Pathol Surg.* 2016;2(1):1–4. doi:10.15713/ins.jmrps.56.
23. He P, Fan SY, Guan JQ, Song WJ, Obore N, Chen WQ, et al. Mediation analysis for the relationship between dyslipidemia and coronary artery disease via hypersensitive C-reactive protein in a case-control study. *Coron Artery Dis.* 2020;31(7):613–619. doi:10.1097/MCA.0000000000000911.

24. Patil V, Avhad A, Kulkarni A, Pandere K. High-sensitive C-reactive protein in patients with coronary artery disease. *J Nat Sci Biol Med.* 2020;11(1):39-44. doi:10.4103/jnsbm.JNSBM\_159\_19.
25. Indrajaya T, Saleh MI, Miliyandra M. The role of high-sensitivity C-reactive protein serum in assessing troponin T in acute myocardial infarction. *Open Access Maced J Med Sci.* 2020;8(B):1053-1056. doi:10.3889/oamjms.2020.5495.

Table 2. Correlation Analysis Between Glycemic Control Parameters and Cardiovascular Risk Markers

		Hs-CRP
<b>HbA1C</b>	spearman	.386**
	Correlation	
	Sig.(2-tailed)	.003*
<b>Systolic blood pressure</b>	spearman	.311**
	Correlation	
	Sig.(2-tailed)	.016*
<b>Diastolic blood pressure</b>	spearman	.092
	Correlation	
	Sig.(2-tailed)	.487

Spearman

\*Correlation is significant at the 0.05 level (2-tailed)

\*\*Correlation is significant at the 0.01 level (2-tailed)

<b>Manuscript review checklist</b>		
Title: Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and hs-CRP Levels in Type 2 Diabetes Mellitus		
	Adequate	Needs revision
TITLE	√	
Not more than 15 words		
Clearly describes the article	√	
Abstracts should be of approximately 200-300 words		√
Reflects the content of the article		
Keywords: provide 3 – 10 keywords		
<b>INTRODUCTION</b>		
1. Rationale for study (need and significance)	√	
2. Summarizes relevant research to provide context, and explains other authors' findings	√	
3. Describe the novelty of the study	√	
4. Objective of the study	√	
<b>METHODS</b>		
1. The design is suitable for answering the question	√	
2. The sampling is appropriate	√	
3. Data Collection Procedures		√
4. Measurements have been described		√
5. Data Analysis (Description of Statistical Evaluation)	√	
<b>C. RESULTS</b>		
1. Detail in narrative of the findings	√	
2. Descriptive quality of figures and tables (if relevant)	√	
3. Clearly laid out and in a logical sequence	√	
4. The analysis has been conducted appropriately		√
<b>DISCUSSION</b>		
1. Findings compared and contrasted with relevant literature	√	
2. The results support or contradict previous theories	√	
3. Limitations of the study		√
4. Clinical implications of the study	√	
5. Future directions of the study		√
<b>CONCLUSIONS</b>		
1. Drawn logically	√	
<b>ACKNOWLEDGEMENT</b>		
<b>AUTHOR CONTRIBUTION</b>		
<b>FUNDING STATEMENT</b>		
<b>CONFLICT OF INTEREST</b>		
<b>REFERENCES</b>		
1. Compliance with journal format (Vancouver style)	√	
2. The minimal number of references should be 20 and 85% of them should be recent (published during the last 10 years, with the majority during the last 5 years)	√	
3. Abbreviate journal names according to the Index Medicus system		√
4. The total number of tables and figures not more than 5	√	

## Reviewer's advises for author(s)

### Abstrak:

1. Adanya ketidakkonsistensi dalam metodologi di abstrak dengan Hasil, yaitu Pearson di abstrak dan metode vs Spearman pada tabel 2.

### Metode:

1. Pengambilan sampel: Justifikasi ukuran sampel (n=59) - tidak ada *power analysis*, padahal dengan jumlah sampel yang kecil maka risiko kesalahan tipe II menjadi lebih besar. Sebaiknya tambahkan perhitungan powernya misal  $\alpha=0,05$ ,  $\beta=0,80$  dan ukuran efek yang diharapkan berdasarkan penelitian sebelumnya.
2. Faktor perancu: Tidak disebutkan pengendalian IMT, profil lipid, atau obat-obatan (misalnya, statin, antiinflamasi), contoh: metformin dapat mempengaruhi hs-CRP. Akan lebih baik menambahkan analisis multivariat misal regresi linier untuk meng-adjust perancu-perancu yang penting.
3. Kriteria eksklusi: Sebutkan apakah NSAID/steroid dikecualikan (mempengaruhi hs-CRP).
4. Klarifikasi kit ELISA yang digunakan (Protokol lab Prodia?)

### Hasil:

1. Ketidakkonsistenan dalam pemilihan metode statistik: Abstrak dan Metode menuliskan Pearson (Abstrak  $r=0,290$ ), namun pada Tabel 2 menggunakan Spearman ( $r=0,386$ ).
2. Tabel 1: Unit yang hilang untuk hs-CRP (mg/L). Kriteria "kontrol glikemik" memerlukan sitasi (apakah kriteria diambil dari ADA/IDF?).

### Pembahasan/Discussion:

1. Keterbatasan: Tidak dibahas (misalnya, sampel kecil, desain potong lintang, sisa faktor perancu).
  2. Temuan yang kontradiktif: Kontradiksi dengan Sari (2023) dicatat tetapi tidak dijelaskan secara memadai; akan lebih baik jika dibahas lebih mendalam misalnya perbedaan kohortnya, atau metode pemeriksaannya, dll.
  3. Dapat menambahkan saran untuk arah penelitian ke depan, misalnya penelitian longitudinal atau intervensi untuk konfirmasi.
- Perbaikan: Tambahkan bagian keterbatasan; diskusikan kemungkinan alasan untuk hasil yang berbeda (misalnya, perbedaan populasi, sensitivitas uji), dan tambahkan saran penelitian ke depan.

### Referensi

1. Jumlah komposisi referensi sudah memenuhi persyaratan, namun dapat dipertimbangkan untuk mengganti referensi no.17 dan 21 dengan meta-analisis yang lebih mutakhir.
2. Untuk jurnal internasional, gunakan singkatan sesuai yang terdaftar di [NCBI Journal Abbreviation List](#).

Untuk jurnal lokal/tidak terindeks, gunakan nama lengkap jurnal untuk menghindari kebingungan, karena tidak ada *standard abbreviation*.



## ORIGINAL ARTICLE

### Glycemic Control and Cardiovascular Risk Assessment: A Study on HbA1c and Hs-CRP Levels in Type 2 Diabetes Mellitus

Kontrol Glikemik dan Penilaian Risiko Kardiovaskular: Studi Kadar HbA1c dan Hs-CRP pada Diabetes Melitus Tipe 2

Mustika Anggiane Putri<sup>1</sup>, Patwa Amani<sup>1</sup>, Donna Adriani<sup>1</sup>, Yudhisman Imran<sup>2</sup>

<sup>1</sup> Departement of Physiology, Faculty of medicine, Universitas Trisakti, Jakarta, Indonesia

<sup>2</sup> Department of Neurology, Faculty of medicine, Universitas Trisakti, Jakarta, Indonesia

[inge.mustika@trisakti.ac.id](mailto:inge.mustika@trisakti.ac.id) (Correspondence email)

<https://doi.org/10.56186/jkbb.xxx>

#### ABSTRACT

##### Background:

Type 2 diabetes mellitus (T2DM) represents a major risk factor for cardiovascular disease. Diabetic patients have a 2-4 fold higher risk of developing coronary heart disease compared to the non-diabetic population. Cardiovascular complications constitute the leading cause of morbidity and mortality in diabetic patients, with cardiovascular disease-related deaths accounting for 65-75% of total mortality in the diabetic population. Poor glycemic control serves as a key factor in the pathogenesis of cardiovascular complications in diabetes. Chronic hyperglycemia triggers various pathophysiological mechanisms, including increased oxidative stress, systemic inflammation, endothelial dysfunction, and accelerated atherosclerotic processes. Hemoglobin A1C (HbA1C) as a parameter of long-term glycemic control has been proven to strongly correlate with the risk of microvascular and macrovascular complications in diabetes. This study aims to analyze the correlation between glycemic control assessed through HbA1C and systemic inflammatory status measured through Hs-CRP as a predictor of cardiovascular risk in patients with type 2 diabetes mellitus.

##### Methods:

An analytical cross-sectional study on 53 T2DM patients at the Prolanis Clinic in East Jakarta (purposive sampling). HbA1c examination using the HPLC method and Hs-CRP using the Turbidimetric Immunoassay method were conducted at PRODIA laboratory. Correlation was analyzed using Spearman's correlation test.

##### Results:

The study revealed a mean HbA1C level of 7.2% and a mean Hs-CRP level of 2.9 mg/L. Statistical analysis demonstrated a significant correlation between HbA1C and Hs-CRP (p-value = 0.014) with a Spearman correlation coefficient of 0.336.

**Conclusion:** There is a significant positive correlation between HbA1c and Hs-CRP levels.

**Keywords:** Cardiovascular risk; type 2 diabetes mellitus; HbA1C; Hs-CRP; inflammation

## ABSTRAK

### Latar Belakang:

Diabetes melitus tipe 2 (T2DM) merupakan faktor risiko utama penyakit kardiovaskular. Pasien diabetes memiliki risiko 2-4 kali lebih tinggi mengalami penyakit jantung koroner dibandingkan populasi non-diabetes. Komplikasi kardiovaskular menjadi penyebab utama morbiditas dan mortalitas pada pasien diabetes, dengan angka kematian akibat penyakit kardiovaskular mencapai 65-75% dari total kematian populasi diabetes. Kontrol glikemik yang buruk menjadi faktor kunci patogenesis komplikasi kardiovaskular pada diabetes. Hiperglikemia kronis memicu berbagai mekanisme patofisiologis, termasuk peningkatan stres oksidatif, inflamasi sistemik, disfungsi endotel, dan percepatan proses aterosklerosis. Hemoglobin A1C (HbA1C) sebagai parameter kontrol glikemik jangka panjang telah terbukti berkorelasi kuat dengan risiko komplikasi mikrovaskular dan makrovaskular pada diabetes. Penelitian ini bertujuan menganalisis korelasi antara kontrol glikemik yang dinilai melalui HbA1C dengan status inflamasi sistemik yang diukur melalui Hs-CRP sebagai predictor risiko kardiovaskular pada pasien diabetes melitus tipe 2.

**Metode:** Studi potong lintang analitik pada 53 pasien T2DM di Klinik Prolanis Jakarta Timur (purposive sampling). Pemeriksaan HbA1c dengan metode HPLC dan Hs-CRP dengan metode Turbidimetric Immunoassay dilakukan di laboratorium PRODIA. Korelasi dianalisis menggunakan uji korelasi Spearman.

**Hasil:** pada studi ini didapatkan rerata kadar HbA1C adalah 7.2% dan rerata Hs-CRP adalah 2.9 mg/L. Analisis statistik menunjukkan korelasi signifikan antara HbA1C dan Hs-CRP (p-value = 0.014) dengan koefisien korelasi Spearman 0.336.

**Kesimpulan:** Terdapat korelasi positif yang signifikan antara kadar HbA1c dan Hs-CRP

**Kata kunci:** Diabetes melitus tipe 2; HbA1C; hsCR; inflamasi

## INTRODUCTION

The global prevalence of type 2 diabetes mellitus (T2DM) has demonstrated a significant escalation attributable to alterations in human lifestyle patterns and behavioral modifications.<sup>1,2</sup> Diabetes has emerged as a predominant cardiometabolic disorder, affecting 10.5% of the adult population (aged 20-79 years) in 2021, with projections indicating an increase to 12.2% by 2045.<sup>2,3</sup> The prevalence exhibits higher rates in urban areas (12.1%) compared to rural regions (8.3%), and in high-income countries (11.1%) versus low-income nations (5.5%). The most substantial relative increase is projected to occur in middle-income countries (21.1%) compared to high-income (12.2%) and low-income countries (11.9%). In Indonesia, T2DM prevalence demonstrates an alarming trend, with continuously rising incidence rates paralleling societal changes in lifestyle and dietary patterns.<sup>1</sup>

Diabetes mellitus extends beyond an isolated health concern, constituting a principal risk factor for cardiovascular disease. Diabetic patients exhibit a 2-4 fold elevated risk of developing coronary heart disease compared to non-diabetic populations.<sup>4</sup> Cardiovascular complications represent the primary cause of morbidity and mortality in diabetic patients, with cardiovascular-related deaths accounting for 65-75% of total mortality in the diabetic population.<sup>4,5</sup> Poor glycemic control serves as a pivotal factor in the pathogenesis of cardiovascular complications in diabetes. Chronic hyperglycemia triggers various pathophysiological mechanisms, including enhanced oxidative stress, systemic inflammation, endothelial dysfunction, and accelerated atherosclerosis.<sup>1</sup> This condition creates a vicious cycle that accelerates the progression of cardiovascular disease in diabetic patients.<sup>1,2</sup>

**Commented [MOU1]:** Penulisan sumber rujukan superskript tanpa tanda kurung  
Contoh :  
...lifestyle patterns and behavioral modifications.<sup>1,2</sup>

**Commented [mp2R1]:** done

Hemoglobin A1C (HbA1C), as a long-term glycemic control parameter, has been demonstrated to correlate with microvascular and macrovascular complications in diabetes.<sup>6</sup> HbA1C reflects the average blood glucose levels over the preceding 8-12 weeks and serves as the gold standard for monitoring glycemic control in diabetic patients. The American Diabetes Association has recognized an HbA1c level of 6.5% or higher as a diagnostic threshold for diabetes and an HbA1c level of >7% as a poor glycemic control.<sup>6</sup> Conversely, high-sensitivity C-Reactive Protein (Hs-CRP) represents a sensitive systemic inflammatory biomarker that has been recognized as an independent predictor of cardiovascular risk. Low-grade chronic inflammation constitutes a crucial characteristic of type 2 diabetes mellitus and plays a significant role in the development of cardiovascular complications.<sup>7</sup> Elevated Hs-CRP levels in diabetic patients not only reflect systemic inflammatory status but also correlate with glycemic control levels and future cardiovascular event risk.<sup>8,9</sup> Given the concerning projected increase in diabetes prevalence, particularly in middle-income countries such as Indonesia, the identification of predictive biomarkers for cardiovascular risk becomes critically important for timely preventive interventions. Therefore, understanding the relationship between glycemic control and inflammatory status becomes essential in the comprehensive management of diabetic patients.

This study aims to analyze the correlation between glycemic control assessed through HbA1C and systemic inflammatory status measured through Hs-CRP in T2DM patients. Although the relationship between glycemic control and cardiovascular complications in type 2 diabetes mellitus has been extensively documented, research specifically analyzing the correlation between HbA1C and Hs-CRP as systemic inflammatory biomarkers in the Indonesian population remains limited. This study contributes novel insights into understanding the interaction between long-term glycemic control and chronic inflammatory status in T2DM patients in Indonesia, who possess distinct demographic and genetic characteristics compared to Western populations.

## **METHODS**

This analytical cross-sectional study was conducted among participants of the Prolanis Diabetes Clinic in East Jakarta. The total clinic population consisted of 64 individuals with T2DM, of whom 53 subjects were included using purposive sampling. Five people were excluded due to absence during blood collection, and 6 people were excluded for showing Hs-CRP results > 10 mg/L (indicating the presence of acute systemic inflammation that could be caused by various diseases).<sup>10</sup> Eligible participants were men and women aged 40–60 years with a diagnosis of T2DM. Exclusion criteria included any known cardiovascular, neurological, malignancy, or pulmonary diseases, as well as any current illness or history of inflammatory conditions that could affect Hs-CRP levels, such as rheumatoid arthritis, gout, or infections.

To justify the sample size, a power estimation was conducted based on the correlation coefficient ( $r = 0.81$ ) reported in a previous study by Reddy et al. (2024)<sup>6</sup>, which found a strong positive relationship between HbA1c and Hs-CRP levels in patients with T2DM and myocardial infarction. Assuming a significance level of 0.05 and statistical power of 80% ( $\beta = 0.20$ ), the minimum number of subjects required to detect a statistically significant correlation of similar strength would

be considerably less than the 53 subjects included in this study. Therefore, the chosen sample size was considered statistically adequate and appropriate for the study objective.

Venous blood samples were collected and processed by the certified PRODIA Laboratory for HbA1c and Hs-CRP. HbA1c were measured using HPLC standardized under the National Glycohemoglobin Standardization Program (NGSP) with Tina-quant HbA1c kit on Cobas Integra analyzer, serving as a marker of long-term glycemetic control. Hs-CRP levels were determined using a validated turbidimetric immunoassay method with i-CHROMA™ hsCRP-ALL in one kit (Boditech Med Inc) to assess systemic inflammation and cardiovascular risk.

The study protocol was reviewed and approved by the Ethics Committee of the Faculty of Medicine, Trisakti University (No.055/KER/FK/II/2023). Descriptive statistics were used for demographic and clinical characteristics, with means and standard deviations for continuous variables and percentages for categorical data. The correlation between HbA1c and Hs-CRP was analyzed using Spearman's rank correlation test. Data analysis was performed using SPSS software.

## RESULTS

The distribution of subject characteristics based on gender, age, blood pressure, HbA1C levels, and Hs-CRP is presented in Table 1. This study involved 53 subjects with T2DM, comprising 36 females (67.9%) and 17 males (32.1%). The age distribution revealed that the majority of subjects were within the 40-60 years age range, accounting for 40 individuals (75.5%), while 13 subjects (24.5%) were aged >60 years.

The mean systolic and diastolic blood pressure values in this study demonstrated a mean systolic blood pressure of 138.2 mmHg and a diastolic blood pressure of 87.7 mmHg. The mean HbA1C level among subjects was 7.2%, indicating poor glycemetic control. The study results showed a mean Hs-CRP level of 2.9 mg/dL, indicating an intermediate risk. Cardiovascular risk assessment using Hs-CRP levels according to American Heart Association criteria revealed that 8 participants (15.1%) had low risk (Hs-CRP <1 mg/L), 28 participants (52.8%) had intermediate risk (Hs-CRP 1.0-3.0 mg/L), and 17 participants (32.1%) had high risk (Hs-CRP >3 mg/L).<sup>11</sup>

A non-parametric Spearman correlation analysis was conducted to examine the correlation between glycemetic control parameters, hemodynamic variables, and Hs-CRP as a cardiovascular risk predictor among 53 patients with T2DM. The results of the correlation analysis are presented in Table 2. The analysis revealed a statistically significant positive correlation between HbA1c levels and Hs-CRP concentrations ( $r = 0.336$ ,  $p = 0.014$ ). This correlation indicates that elevated HbA1c levels are associated with increased Hs-CRP levels, suggesting a correlation between poor glycemetic control and cardiovascular risk in diabetic patients.

Regarding hemodynamic parameters, systolic blood pressure demonstrated a significant positive correlation with Hs-CRP levels ( $r = 0.277$ ,  $p = 0.044$ ). This finding suggests that elevated systolic blood pressure is associated with increased inflammatory markers, potentially indicating the role of hypertension in cardiovascular risk enhancement through inflammatory pathways. Conversely, diastolic blood pressure showed no significant correlation with Hs-CRP levels ( $r = 0.059$ ,  $p = 0.673$ ).

## DISCUSSIONS

Based on the research data presented in Table 2, there is a distinct pattern of relationship between Hs-CRP and the components of systolic and diastolic blood pressure. The Spearman correlation analysis revealed a significant relationship between Hs-CRP and systolic blood pressure ( $r = 0.277$ ,  $p = 0.044$ ); however, no significant relationship was found with diastolic blood pressure ( $r = 0.059$ ,  $p = 0.673$ ). This finding provides an interesting insight into how systemic inflammatory markers interact with cardiovascular hemodynamic parameters in patients with type 2 diabetes mellitus.<sup>8,9</sup> Previous studies have established the relationship between diabetes and the occurrence of hypertension.<sup>12</sup> Diabetes and hypertension can increase the risk of each other, and when they occur together, they significantly elevate the risk of cardiovascular disease.<sup>12-14</sup>

Hs-CRP is an inflammatory marker produced by the liver and elevated during inflammation, including in the process of atherosclerosis, and has been proven as a marker that can predict cardiovascular disease risk.<sup>6</sup> This study demonstrated a significant relationship between systolic blood pressure and Hs-CRP but not with diastolic blood pressure. This phenomenon can occur because systolic blood pressure is more sensitive to vascular inflammatory changes compared to diastolic pressure, as systolic pressure reflects the strength of cardiac contraction and the elasticity of larger arterial blood vessels.<sup>15</sup> When chronic inflammation occurs, as indicated by increased Hs-CRP, arterial walls become stiffer and less elastic, which directly affects systolic pressure.<sup>15</sup> Conversely, diastolic pressure more reflects the resistance of smaller peripheral blood vessels and is not significantly influenced by inflammatory processes occurring in larger blood vessels.<sup>14</sup> Poor glycemic conditions trigger systemic inflammation that increases Hs-CRP.<sup>1,2,6</sup> This inflammation contributes to arterial stiffening, which has a greater impact on the systolic component of blood pressure.<sup>15</sup> Therefore, Hs-CRP as a predictor of cardiovascular inflammation demonstrates a stronger correlation with systolic pressure because both reflect vascular damage occurring in major arterial blood vessels, while diastolic pressure remains more stable and is not significantly affected by systemic inflammatory changes measured through Hs-CRP.<sup>15-16</sup>

High blood pressure (hypertension) and diabetes frequently occur simultaneously and increase the risk of cardiovascular disease. Elevated blood glucose levels and high blood pressure can damage the vascular endothelium, subsequently leading to the formation of atherosclerosis.<sup>4</sup> <sup>5</sup> The fundamental concept of atherosclerosis is arterial hardening due to the gradual accumulation of fatty plaques within the vessel walls. This plaque accumulation restricts blood flow.<sup>4</sup>

Atherosclerosis begins with endothelial activation, followed by a cascade of events (lipid accumulation, fibrous proliferation).<sup>5</sup> Non-enzymatic glycation reactions between glucose and proteins or lipoproteins in arterial walls represent one of the important mechanisms responsible for accelerated atherosclerosis formation under hyperglycemic conditions in type 2 diabetes mellitus.<sup>15</sup> Prolonged exposure to hyperglycemia is believed to be a primary factor in the pathogenesis of atherosclerosis in diabetes. Hyperglycemia induces numerous changes at the cellular level of vascular tissue that potentially accelerate the atherosclerotic process.<sup>17-18</sup>

Another important biochemical process accompanying type 2 diabetes mellitus is the formation of Advanced Glycation End Products (AGEs). These AGEs likely also underlie the general inflammatory process.<sup>19</sup> The formation and accumulation of AGEs are associated with aging processes and are accelerated in diabetes.<sup>20</sup> AGEs are produced under hyperglycemic conditions,

but their production also occurs in situations characterized by oxidative stress and inflammation.<sup>18</sup> Activation of AGE receptors can induce cascading inflammatory responses that cause increased inflammation, oxidative stress, enhanced calcium deposition, and increased vascular smooth muscle apoptosis. This contributes to the development of atherosclerosis.<sup>21</sup>

The synergistic reaction between hypertension and hyperglycemia causes atherosclerosis formation through at least two mechanisms: elevated hemodynamic pressure in hypertensive conditions damages the endothelium and upregulates the renin-angiotensin-aldosterone system, oxidative stress, and inflammation, which contribute to the close relationship between diabetes and hypertension.<sup>22</sup>

High-sensitivity C-reactive protein (Hs-CRP) is a systemic inflammatory marker that emerges as an independent risk factor for cardiovascular disease.<sup>23-24</sup> Elevated Hs-CRP levels are associated with increased risk of thrombotic events, including myocardial infarction. Increased Hs-CRP levels are also associated with increased risk of developing diabetes later in life. Furthermore, it has been found that Hs-CRP levels are higher in diabetic patients compared to those without diabetes.<sup>25-27</sup> This study demonstrated that Hs-CRP and HbA<sub>1c</sub> showed a significant relationship between them. This is consistent with studies conducted by Seo HY, Khairinisa G, and Reddy KSS, which stated that HbA<sub>1c</sub> levels increased significantly with increasing Hs-CRP.<sup>6,7</sup> In contrast to the study conducted by Sari EP (2023), which stated that her study results showed no significant correlation between HbA<sub>1c</sub> levels and CRP (p-value=0.171 and r=0.218).<sup>8</sup> The key differences between this study and Sari EP (2023) involve measurement sensitivity and sample size. Sari used a semi-quantitative latex agglutination method for CRP with a detection threshold of 0.6 mg/dL (6 mg/L), which is less sensitive for detecting low-grade inflammation compared to our validated turbidimetric immunoassay capable of measuring Hs-CRP below 0.1 mg/L. Hs-CRP's superior sensitivity allows identification of subtle inflammatory changes specifically relevant to cardiovascular risk assessment. The sample size difference is also crucial; Sari's 24 subjects versus our 53 participants significantly affects statistical power to detect associations.<sup>8</sup>

Hs-CRP directly participates in the pathogenesis of atherosclerosis through the inflammation of endothelial cells and coronary arterial smooth muscle cells. Hs-CRP levels in various morbidity and mortality assessments are considered as one of the factors taken into account and as one of the predictor factors added to the Framingham score that enhances cardiovascular risk prediction. While this study identified a statistically significant correlation between HbA<sub>1c</sub> and Hs-CRP, potential confounding factors must be acknowledged. Variables such as BMI, lipid profile, and medications—particularly statins, anti-inflammatory agents, and metformin—are known to influence systemic inflammation. Previous studies demonstrate that metformin reduces Hs-CRP levels by suppressing proinflammatory cytokine secretion in hepatocytes and macrophages, indicating anti-inflammatory properties beyond glucose control.<sup>28</sup> However, due to data limitations, these variables were not adjusted for in the current analysis. Future studies incorporating multivariable regression models are warranted to control for confounding variables and clarify the independent relationship between glycemic control and systemic inflammation.

## CONCLUSIONS

This study demonstrates a significant positive correlation between HbA1c and Hs-CRP levels in T2DM, indicating that poor glycemic control is associated with increased systemic inflammation. Additionally, Hs-CRP showed a significant correlation with systolic blood pressure but not with diastolic blood pressure, suggesting that inflammatory markers preferentially affect arterial stiffness and larger vessel dynamics. These findings support the use of Hs-CRP as a valuable biomarker for cardiovascular risk assessment in diabetic patients, particularly when combined with glycemic control parameters.

## ACKNOWLEDGEMENT

The authors would like to express their sincere gratitude to all research team members who contributed to the successful completion of this study. We also acknowledge the support provided by the participants and the medical staff who facilitated data collection.

## AUTHORS CONTRIBUTION

The concept, analysis, and interpretation of data, drafting manuscript: Putri MA. Collecting data, assisted in developing research methodology: MAP, PA, DA, YI. Critical review of the manuscript: PA, DA, YI.

## FUNDING

This research was supported by an internal grant from Trisakti University.

## CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose

## REFERENCES

1. Gudisa B, Gemechis B. The incidence and predictors of poor glycemic control among adults with type 2 diabetes mellitus in ambulatory clinic of Mettu Karl Referral Hospital, South Western, Ethiopia: a prospective cross sectional study. *Int Arch Endocrinol Clin Res.* 2021;7(1). DOI:10.23937/2572-407X.1510024.
2. Rosengren A, Dikaïou P. Cardiovascular outcomes in type 1 and type 2 diabetes. *Diabetologia.* 2023;66:425–37. DOI:10.1007/s00125-022-05857-5.
3. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract.* 2022;183:109-19. DOI: 10.1016/j.diabres.2021.109119.
4. Verma S, Leiter LA. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. *Can J Cardiol.* 2018;34(5):575–84. DOI:10.1016/j.cjca.2017.12.005.
5. Rodriguez-Araujo G, Nakagami H. Pathophysiology of cardiovascular disease in diabetes mellitus. *Cardiovasc Endocrinol Metab.* 2018;7(1):4–9. DOI:10.1097/XCE.000000000000141.

### Commented [MOU3]: Perbaiki :

1. Penulisan nama author: setelah 3 author, dilanjutkan et al
2. Nama Jurnal, disingkat sesuai [https://www.issn.org/wp-content/uploads/2024/02/itwa\\_current.pdf](https://www.issn.org/wp-content/uploads/2024/02/itwa_current.pdf)
3. Penulisan halaman bila puluh atau ratus nya sama, maka tidak ditulis :  
Contoh 575-584 → 575-84
4. Penulisan doi dalam huruf besar : doi → DOI

6. Reddy KSS, Varadaraj P, Nallusamy G, et al. Correlation between hemoglobin A1c (HbA1c) and high-sensitivity C-reactive protein (Hs-CRP) in myocardial infarction patients and their six-month mortality follow-up. *Cureus*. 2024;16(8):e67070. DOI:10.7759/cureus.67070.
7. Seo YH, Shin HY. Relationship between Hs-CRP and HbA1c in diabetes mellitus patients: 2015–2017 Korean National Health and Nutrition Examination Survey. *Chonnam Med J*. 2021;57(1):62–8. DOI:10.4068/cmj.2021.57.1.62.
8. Sari EP, Sayekti S. Korelasi kadar HbA1c dengan C-reactive protein pasien diabetes melitus tipe 2. *Jurnal Sintesis Penelitian Sains Terapan dan Analisisnya*. 2023;4(1):1–7. DOI:10.56399/jst.v4i1.102.
9. Venkatamani Y, Raj JR, Ahmed MI, et al. Study of C-reactive protein, D-dimer in correlation with HbA1c levels in patients with diabetes mellitus type 2. *Panacea J Med Sci*. 2023;13(1):72–7. DOI:10.18231/j.pjms.2023.016.
10. Wolska A, Remaley AT. CRP and High-Sensitivity CRP: "What's in a Name?". *J Appl Lab Med*. 2022;7(6):1255-1258. DOI: <https://doi.org/10.1093/jalm/jfac076>
11. Johns I, Moschonas KE, Medina J, et al. Risk classification in primary prevention of CVD according to QRISK2 and JBS3 'heart age', and prevalence of elevated high-sensitivity C-reactive protein in the UK cohort of the EURIKA study. *Open Heart*. 2018;5:e000849. DOI:10.1136/openhrt-2018-000849
12. Wang B, Yang Y, Li X. Interaction of hypertension and insulin resistance exacerbates the occurrence of diabetes mellitus in healthy individuals. *J Diabetes Res*. 2022;2022:1–8. DOI:10.1155/2022/1234567.
13. Midha T. Correlation between hypertension and hyperglycemia among young adults in India. *World J Clin Cases*. 2015;3(2):171–6. DOI:10.12998/wjcc.v3.i2.171.
14. Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, et al. Hypertension and diabetes mellitus coprediction and time trajectories. *Hypertension*. 2018;71(3):422–8. DOI:10.1161/HYPERTENSIONAHA.117.10546.
15. Kim HL. Arterial stiffness and hypertension. *Clin Hypertens*. 2023;29(1):31. DOI:10.1186/s40885-023-00258-1.
16. Kandil H, Soliman A, Alghamdi NS, et al. Using mean arterial pressure in hypertension diagnosis versus using either systolic or diastolic blood pressure measurements. *Biomedicines*. 2023;11(3):849. DOI:10.3390/biomedicines11030849.
17. Geraghty L, Wood MJ. Cardiovascular disease in women: from pathophysiology to novel and emerging risk factors. *Heart Lung Circ*. 2021;30(1):9–17. DOI:10.1016/j.hlc.2020.05.108.
18. Schmidt AM. Diabetes mellitus and cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 2019;39(4):558–66. DOI:10.1161/ATVBAHA.119.310961.
19. Lee J, Yun JS, Ko SH. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. *Nutrients*. 2022;14(15):3086. DOI:10.3390/nu14153086.
20. Mao L, Yin R, Yang L, et al. Role of advanced glycation end products on vascular smooth muscle cells under diabetic atherosclerosis. *Front Endocrinol (Lausanne)*. 2022;13:983723. DOI:10.3389/fendo.2022.983723.
21. Putri MA, Amani P, Adriani D, et al. Importance of exercise in mitigating age-related cardiac apoptosis. *Sriwijaya Journal of Medicine*. 2023;6(3):94–101. DOI:10.32539/sjm.v6i3.208.

22. Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. *Circ Res.* 2020;126(11):1501–25. DOI:10.1161/CIRCRESAHA.120.315913.
23. Dayoub A, Khayat MI, Zrieki A. Association of high sensitivity C-reactive protein (Hs-CRP) with poor glycaemic control and coronary heart disease in type 2 diabetes mellitus. *Res J Pharm Technol.* 2023;16(1):193–9. DOI:10.52711/0974-360X.2023.00036.
24. Sasidharan A, Krishnamurthy A, Tagore S, et al. C-reactive protein and glycemic control in adults with type 2 diabetes mellitus. *J Med Radiol Pathol Surg.* 2016;2(1):1–4. DOI:10.15713/ins.jmrps.56.
25. He P, Fan SY, Guan JQ, et al. Mediation analysis for the relationship between dyslipidemia and coronary artery disease via hypersensitive C-reactive protein in a case-control study. *Coron Artery Dis.* 2020;31(7):613–9. DOI:10.1097/MCA.0000000000000911.
26. Patil V, Avhad A, Kulkarni A, et al. High-sensitive C-reactive protein in patients with coronary artery disease. *J Nat Sci Biol Med.* 2020;11(1):39–44. DOI:10.4103/jnsbm.JNSBM\_159\_19.
27. Indrajaya T, Saleh MI, Miliyandra M. The role of high-sensitivity C-reactive protein serum in assessing troponin T in acute myocardial infarction. *Open Access Maced J Med Sci.* 2020;8(B):1053–6. DOI:10.3889/oamjms.2020.5495.
28. Karbalaee-Hasani A, Khadive T, Eskandari M, et al. Effect of Metformin on Circulating Levels of Inflammatory Markers in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Ann Pharmacother.* 2021;55(9):1096–109. DOI:10.1177/1060028020985303.

**Table 1.** Distribution of Subject Characteristics

Variable	Frequency	min	max	mean±SD
<b>Gender</b>				
Men	17 (32.1%)			
Women	36 (67.9%)			
<b>Age (year)</b>				
40 – 60	40 (75.5%)			
>60	13 (24.5%)			
<b>Inflammation risk categories</b>				
Low risk (< 1.0 mg/L)	8 (15.1%)			
Intermediate risk ( 1.0 – 3.0 mg/L)	28 (52.8%)			
High risk (>3.0 mg/L)	17 (32.1 %)			
<b>Tekanan Darah</b>				
Sistolik (mmHg)		100	202	138.2 ± 19.6
Diastolik (mmHg)		70	115	87.7 ± 9.2
<b>Serum Level</b>				
HbA1c (%)		4.8	11.3	7.2 ± 1.8
Hs-CRP (mg/L)		0.3	9.7	2.9 ± 2.4

**Commented [MOU4]:** Mohon perbaiki, penulisan desimal menggunakan titik  
Contoh : 69.5

**Table 2.** Correlation Analysis Between HbA1C, Blood Pressure and Hs-CRP

		Hs-CRP
<b>HbA1C</b>	spearman	.336**
	Correlation	
	Sig.(2-tailed)	.014*
<b>Systolic blood pressure</b>	spearman	.277**
	Correlation	
	Sig.(2-tailed)	.044*
<b>Diastolic blood pressure</b>	spearman	.059
	Correlation	
	Sig.(2-tailed)	.673

Spearman

\*Correlation is significant at the 0.05 level (2-tailed)

\*\*Correlation is significant at the 0.01 level (2-tailed)